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ABSTRACT
CHERYL R. STEIN: Chlamydial Infection among Young Adults:
Selective Screening and Partner Age Difference
an Investigation of the National Longitudinal Study of Adolescent Health
(Under the direction of William C. Miller)
Among young adults, chlamydial infection is the most common bacterial sexually
transmitted infection. Women and minorities are most affected. Screening rates are low
despite recommendations for yearly testing. Programs to expand testing to community
settings may increase screening rates. To examine this and other questions, we conducted a
cross-sectional analysis of Wave III of the National Longitudinal Study of Adolescent Health
(April 2, 2001 – May 9, 2002). Chlamydia trachomatis test results were available for 10,928
(88.6%) of the sexually experienced participants.
First, we developed selective screening guidelines for community settings.
Separately for women and men, we developed three predictive models using unconditional
multiple logistic regression. The initial models included predictor characteristics plus
information on 1) respondent’s race/ethnicity; or 2) respondent’s most recent partner’s
race/ethnicity; or 3) no information on race/ethnicity. A combination of characteristics
provides potentially useful screening tools. Applying these models to select  50 percent of
the population for diagnostic testing identifies approximately 80 percent of infections in
women and men. Using race/ethnicity in any screening algorithm is controversial and may
have significant consequences. The model without race information, however, resulted in
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many missed diagnoses in the minority group. Universal screening for chlamydial infection
may be the only approach that reaches high prevalence populations while avoiding the stigma
of screening guidelines incorporating race/ethnicity.
Second, we evaluated the association between partner age difference and chlamydial
infection among young women. Adolescent girls with older male partners are at higher risk
of STI compared to girls with partners their own age, but whether this association continues
beyond adolescence is unclear. After multiple logistic regression, the odds of prevalent
chlamydial infection among women with partners two to eight years younger were nearly
two times greater (odds ratio (OR) 1.8, 95% confidence interval (CI) 0.9 – 3.5) than partners
within one year’s age. Among women with older partners, the adjusted odds of infection
were similar for partners two to five years older (OR 1.4, 95% CI 0.9 – 2.3) and partners six
to 36 years older (OR 1.6, 95% CI 0.9 – 2.8). Among young adult women, older partners are
moderately associated with prevalent chlamydial infection.
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CHAPTER 1
OVERVIEW
Chlamydia trachomatis, with an estimated three million new infections each year, is
the most common bacterial sexually transmitted infection (STI) in the United States (US),
especially among adolescents and young adults (1). Black, Native American, and Latino
women and men are disproportionately burdened with infection (2, 3). Chlamydial infection
may cause pelvic inflammatory disease, ectopic pregnancy, and tubal infertility in women (4-
6). In vitro studies suggest that C. trachomatis may affect sperm function in men (7). In
both sexes, infection increases susceptibility to and transmission of HIV (8, 9). This STI
causes substantial morbidity, yet it can be prevented using safer sex practices, detected with a
urine-based nucleic acid amplification test, and cured by a single dose of oral antibiotics.
Testing for and treating STI may reduce potential complications, duration of
infection, rates of transmission, and ultimately infection prevalence. However, identifying
who, at a population level, is at risk of infection and would benefit from testing is
challenging. The majority of men and women infected with chlamydia are asymptomatic
(10). It is difficult to encourage people at risk of infection to seek care, as well as to
encourage health care providers to view screening as a public health priority. For these and
other reasons, screening rates for chlamydial infection remain low (11-13) and prevalence of
chlamydial infection remains high (2, 3).
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Urine-based diagnostic tests facilitate STI screening and make testing outside of
traditional sexually transmitted disease (STD) and family planning clinics feasible. These
tests can also be used in survey research to detect infection in the general population,
including hard-to-reach segments like young people. With laboratory diagnostics linked to
detailed demographic, personal history, and behavior data as it is in Wave III of the National
Longitudinal Study of Adolescent Health (Add Health), we have the tools to develop
population-based selective screening guidelines for prevalent chlamydial infection for both
women and men. Additionally, these unique data provide information on sexual partnerships
that can illuminate the association between partner age difference and prevalent chlamydial
infection among young women.
Specific Aim One
Selective Screening Guidelines for Chlamydial Infection in US Young Adults
To develop criteria for screening young women and men in the US general population for
prevalent chlamydial infection.
Hypothesis: The risk of prevalent chlamydial infection can be predicted with reasonable
accuracy using a combination of demographic, behavioral, and clinical variables.
Overview: We will develop screening criteria separately for women and men using data
collected in Add Health Wave III. Demographic, sexual behavior, self-perceived risk,
medical, and health care factors will be analyzed as candidate predictor variables.
Rationale: Testing and treatment for chlamydial infection is challenging because infections
are asymptomatic in approximately 70 percent of women and 50 percent of men (10). The
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US Preventive Services Task Force “strongly recommends” that clinicians routinely screen
all sexually active women aged 25 years or younger for chlamydial infection (14). However,
screening rates are remarkably low (12, 13), despite the inclusion of chlamydial screening in
the Health Plan Employer Data and Information Set (HEDIS) performance measures (11).
Furthermore, chlamydial infection in men is not addressed by current recommendations.
While this STI is a lesser problem among males compared to females (2, 3), a sizeable
proportion of young men are consistently diagnosed with asymptomatic infection (15-17).
Perhaps more importantly, these men may transmit chlamydial infection to their female
partners. Programs to expand testing beyond clinic settings to locations such as community
centers, health fairs, school campuses, and other locations frequented by young people may
help screen more people. Community-based testing is a potentially valuable way to reach
young adults in the general population with asymptomatic infection.
Specific Aim Two
Partner Age Difference and Chlamydial Infection among Young Adult Women
To assess the association between partner age difference and prevalent chlamydial infection
among young adult women.
Hypothesis: Younger women in age-discordant partnerships have higher odds of chlamydial
infection compared to older women in age-discordant partnerships.
Overview: We will describe the range of partner age difference within and across
partnerships using data collected during Add Health Wave III. Partner age difference will be
examined for association with prevalent chlamydial infection women.
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Rationale: Sexual mixing between members of different groups facilitates the spread and
maintenance of STI (18-21). Partner mixing by age is common among both adolescents and
young adults (22, 23). Adolescent girls with older male partners are more likely to practice
sexual behaviors such as young age at first sex and inconsistent condom use, which are risk
factors for STI (24-31). Whether this relation between older partners and risky behavior
continues beyond adolescence is uncertain. Two studies reporting the effect of partner age
difference on STI among adults found little association, but one study diagnosed chlamydial
infection by culture (18) and the other relied on self-report of STI test or treatment in the past
year (23). The effect of another salient risk factor for STI, young age at first sex, does
diminish with increasing age (32). These findings suggest that older male partners may play
a lesser role in risk of STI as adolescent girls mature into adulthood. The knowledge that
partner age difference has a heterogeneous effect on risk of chlamydial infection across age
groups can contribute to an improved understanding of STI epidemiology and may inform
clinical management, health education, and intervention programs.
CHAPTER TWO
BACKGROUND
Prevalence and Public Health Costs of Chlamydial Infection in the United States
Sexually transmitted infections constitute the overwhelming majority of nationally
notifiable disease reporting in the US. In 2004, nearly 1.3 million STI, excluding HIV,
herpes, hepatitis, and human papillomavirus, were reported to the Centers for Disease
Control and Prevention (CDC) (2). These 1.3 million reported cases account only for a
fraction of the 15 million estimated incident infections (33). Even with advancements in
medical technology that permit more facile, less invasive diagnostic testing, and the
availability of effective therapy, overall STI prevalence is rising in the US (2).
Infection with Chlamydia trachomatis is the most commonly reported notifiable
condition in the US (2). The CDC recorded 929,462 chlamydial infections in 2004, but the
true number is estimated to be three million (33, 34).
The long-term sequelae of chlamydial infection are significant. Among women,
infection may cause pelvic inflammatory disease, ectopic pregnancy, tubal infertility, and
chronic pelvic pain (4, 6). Infection may also be linked to cervical cancer (35). Among men,
chlamydial infection may lead to chronic prostatitis, reactive arthritis, urethral strictures, and
possible fertility problems (5, 7). In women and men, chlamydial infection increases
susceptibility to and transmission of HIV (8, 9).
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The direct, indirect, and intangible price of STI is also considerable. The yearly cost
of a single prevalent chlamydial infection, adjusted to 1994 dollars, is $2,630 (36). Expenses
total nearly eight billion dollars a year for the three million estimated annual incident
infections. The estimated lifetime direct medical cost of a new chlamydial infection for
Americans aged 15 to 24 years is 248.4 million dollars (37). This figure includes treating
acute infection and sequelae of untreated or inadequately treated infection, but does not
account for chlamydial infection’s facilitative role in HIV transmission (37).
Prevalence of Chlamydial Infection Varies by Age, Gender, and Race/Ethnicity
The reported prevalence of chlamydial infection varies considerably across
populations and testing situations (Appendix One). The prevalence of chlamydial infection
ranges from a low of 2.1 percent in a convenience sample from a private pediatric practice in
suburban North Carolina (38) to a high of 27.2 percent among females attending teen health
clinics in Atlanta, Georgia (39).
Adolescents (ages 10 to 19 years) and young adults (ages 20 to 24 years) constitute a
disproportionately large segment of the population with STI. While people aged 15 to 24
years comprise about 25 percent of the sexually active population, they account for nearly 50
percent of the STI (1). The highest reported rates of chlamydial infection occur among
females aged 15 to 19 years and males aged 20 to 24 years (2). Minority youth have a higher
reported rate of infection as compared to white youth. In 2004, black, non-Hispanic females
aged 15 to 19 years were infected with chlamydia at a rate of 8,897.6 per 100,000 population,
compared to 2,810.1 per 100,000 for similarly aged Hispanic and 1,408.8 per 100,000 for
white, non-Hispanic females (2). These high rates of nationally reported infection in young
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people, especially among minority young people, are consistently duplicated by population-
based studies (3, 40, 41), and STI screening in high schools (42-44), the military (17, 45, 46),
juvenile detention centers (15, 47, 48), the national job training program (49), and other non-
clinic settings (50) (Appendix One). In the Add Health population, infection prevalence is
highest in women, African Americans, and people from the southern region of the US (3).
Factors Contributing to Chlamydial Infection among Young People
The reasons for high STI prevalence among young people are numerous. Biologic,
cognitive, behavioral, and social factors all contribute to the elevated prevalence. Adolescent
vaginal physiology may increase susceptibility to STI through cervical ectopy, alkaline
vaginal pH, and thin cervical mucous (51). The cognitive development of adolescents further
puts them at risk of infection. Until middle or late adolescence, young people may have
difficulty conceptualizing the long-term impact of current actions (51).
Behavior is often at the essence of STI risk. Adolescents and young adults engage in
behaviors known to increase the rate of STI acquisition. Young age first sex may lead to a
greater number of lifetime sexual partners, an important determinant of STI risk. Multiple
sex partners within a short time period may increase risk behaviors like sequential and
overlapping partners. Condom use is inconsistent and tends to diminish over the course of a
relationship, making sequential partners a risk factor for infection if the gap between partners
is shorter than the duration of infection (51).
Social issues are also intrinsic to the high STI rate among young people. The Institute
of Medicine names the societal problems of poverty, lack of education, and social inequity as
culpable in the STI epidemic (52). The “lack of openness and mixed messages regarding
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sexuality” is an additional cited cause (52). Adults, be they parents, educators, or health care
providers, often fail to share with children the information and tools needed to make timely,
balanced, and informed choices regarding sexual activity (53). Procuring condoms may be
logistically difficult for adolescents; yet making condoms readily available in schools and
other locales frequented by young people remains controversial. Adolescents who want to
access health services for STI counseling, testing, and treatment must know where to access
care, be able to make an appointment, have transportation to the site, and pay for service, all
potentially insurmountable barriers to a young person (53). Furthermore, maintaining patient
confidentiality continues to be an issue when exercising benefits conferred by a parent’s
health insurance (51). These cognitive, behavioral, and social impediments all compound
young people’s innate biologic susceptibility to STI and significantly contribute to the
epidemic spread of infection.
Using the Sexually Transmitted Disease Transmission Model to Reduce Prevalence
The May and Anderson model of STD transmission provides a useful framework for
understanding the links among classical STI risk factors, risk markers, and health care (54,
55). Transmission or reproductive rate is a function of infectivity/transmissibility, the
interaction between susceptibles and infectors, and the duration of infection. The traditional
formula is R0 = *c*D where R0 is the reproductive rate or average number of secondary
cases generated by a primary case;  is a measure of transmissibility; c is a measure of
partner change; and D is duration of infectiousness. Condom use and sexual practices may
affect transmissibility, . Factors related to sexual partners, such as number of partners, rate
of partner change, and concurrent partners affect parameter c. Duration of infection may be
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influenced by immune factors and presence of symptoms. Reproductive rates greater than or
equal to one will propagate or sustain the epidemic. Lowering disease prevalence requires
reducing the reproductive rate by changing any or all of the model’s parameters. Common
interventions and known risk factors and markers can all be linked to specific parameters.
Testing and treatment for STI affect transmission primarily by reducing the duration
of infectiousness, D and consequently the number of secondary cases infected by the index
case (54, 55). Disease screening – testing for disease in the absence of symptoms – is
particularly important for STI where asymptomatic infection is common and may have
prolonged duration resulting in continued transmission over time.
Testing and treatment for chlamydial infection can reduce the overall prevalence of
infection (56, 57) and the incidence of pelvic inflammatory disease (58). Rates of chlamydial
infection dropped by up to 60 percent after the implementation of large-scale screening
programs like the Department of Health and Human Services Region X program in family
planning clinics in Alaska, Idaho, Oregon, and Washington (59). The lowest rates of
chlamydial infection in a study of female military recruits were in women from states with
active screening programs (46). Repeated STI screening through school-based programs also
considerably lowered the prevalence of chlamydial infection among boys, with a lesser effect
among girls (60). The CDC recently proclaimed that “increased screening by healthcare
providers . . .will be necessary to reduce substantially the burden of chlamydial infection in
the United States” (61). The National Commission on Prevention Priorities also named
screening young women for chlamydial infection as an effective clinical preventive service,
but with low implementation (62).
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Screening for STI has proven cost effective in both minimizing disease burden and
sequelae among women (63). Computer models also exhibit substantial cost savings – 1,086
dollars per major outcome averted during 10 years of screening a general population aged 15
to 64 years with a 4.1 percent baseline prevalence of chlamydial infection (64). Screening
may be even more beneficial in populations with higher prevalence of infection. Shortening
duration of infection through screening is a sensible approach to reducing the STI burden
(10, 61).
Infection transmission is related to sexual partnership traits through all three
parameters. While an individual’s rate of partner change affects transmission through c, the
actual characteristics of the partner exert influence through , c, and D. To acquire a STI
from a partner, the partner must be infected. The partner’s risk of STI is shaped by his or her
own sexual behaviors, partner change, and treatment practices.
Although elevated risk is a direct result of sexual behavior, health care, medical
factors, and demographic characteristics such as age, race/ethnicity, and education status may
crudely identify members of different subpopulations with disparate background risk of STI.
An individual who selects a partner from a group with higher risk increases his or her own
risk of STI. Consequently, an individual selecting a partner discordant with respect to age,
race/ethnicity, or even educational attainment may be selecting a partner with a discordant
risk of STI. These associations have been clearly established in small STD clinic populations
(18). Assessing the existence of analogous relationships in the general population,
particularly in a young population where discordant age may be more meaningful, has
potential for shaping future efforts to minimize prevalence by targeting partner choice.
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Asymptomatic Infection Hinders Management of Chlamydial Infection
Untreated infection is a driving force of the STI epidemic. Asymptomatic chlamydial
infection contributes significantly to the complexity of controlling the spread of infection. In
a cross-sectional survey of asymptomatic young adult, military personnel from four settings,
the overall prevalence of chlamydial infection was 4.2 percent (65). Chlamydial infections
are asymptomatic in approximately 70 percent of women and 50 percent of men (10). Men
are more likely to have symptoms and experience a shorter duration of infection.
Getting people at risk of infection to present for screening is challenging in the
absence of typical genitourinary symptoms like pain on urination or discharge. Focus groups
of adolescents have revealed a lack of awareness of the importance of screening to detect
asymptomatic STI as a barrier to screening (53). Health care providers outside of STD
clinics may not evaluate asymptomatic, albeit at-risk patients for STI. Only 42 percent of
primary care providers at a large, integrated health care delivery system reported annual
chlamydial screening of sexually active adolescents (66). Systems-level change in
commercial health plans has boosted screening rates (11). Non-traditional testing venues
may also help improve screening rates, but the lack of screening guidelines applicable to the
largely asymptomatic general population hinders public health efforts to control disease.
Guidelines to be used in community settings should be based on data from the general
population rather than algorithms derived from clinical settings.
24
Testing for Sexually Transmitted Infection
Sensitive and non-invasive tests can diagnose even asymptomatic sexually
transmitted infection and facilitate testing outside of traditional clinic-base settings. Ligase
chain reaction (LCR) for chlamydial infection can be applied to urine specimens and has
excellent performance with sensitivities generally greater than 90 percent and specificities
greater than 99 percent (67-78; Appendix Two). Performing tests on urine specimens is
more acceptable than invasive testing methods, leading to higher rates of test taking,
particularly among asymptomatic populations (79, 80). Identifying and treating disease in
segments of the population broader than symptomatic persons or those attending STD clinics
is crucial to reducing the overall prevalence of STI. Providers wishing to expand screening
services into non-traditional settings, however, have little guidance since screening criteria
developed in STD or family planning clinics may not be appropriate for the general
population.
Current Selective Screening Guidelines are Unsuitable for the General Population
Screening is critical to the early detection and treatment of STI since seeking care
only when symptoms occur will likely miss most infections (14). The CDC (81), American
Medical Association (82), American Academy of Pediatrics (83), American College of
Obstetrics and Gynecology (84), US Preventive Services Task Force (14), and American
College of Preventive Medicine (85) all provide guidelines for chlamydial screening in
women (Appendix Three). Numerous local American and international disease control
programs have also developed selective screening criteria (86-97; Appendix Three). Many
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of these guidelines are based just on age: any sexually active women younger than a
specified age is to be screened for chlamydial infection. Some guidelines attempt to target
specific populations by specifying young age alone or older age plus risk factors. Other
guidelines include age as one of several risk factors. A few guidelines do not incorporate age
at all. The age cutoffs for each of the guidelines are dependent on the study populations used
to develop the guidelines. Unfortunately, when examined across diverse settings, selective
screening criteria often fail to deliver the desired result of detecting most infections with a
minimum number of false positives (46, 98-100). A primary reason for this failure is that
criteria based on STD clinic populations perform poorly in non-clinic testing situations (90).
These guidelines have diminished accuracy in lower prevalence settings with wider ranges of
demographic characteristics and behavioral risk factors (101, 102).
Guidelines developed using data from STD and family planning clinics may not be
applicable to the general population, which is the most suitable population to screen for
asymptomatic disease. The higher infection prevalence in clinic compared to population
settings can affect the scoring of risk assessment criteria. Additionally, demographic and
behavioral characteristics differ between clinic attendees and the general population. A
comparison of patients attending a STD clinic and community residents from the same town
found that while both samples yielded similar estimates of the proportions using condoms
and average age at first intercourse, risky behavior was more common in the clinic
populations (103). The two populations also differed demographically. In another
community there were differences between STD clinic and random digit dialed populations
for all examined individual and partnership characteristics (104). STD clinic patients were
younger at first sex and reported a greater number of lifetime partners, a higher rate of
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partner change, more concurrent partnerships, and a more varied assortment of sexual
activities (104).
Most STI screening criteria only address infection in women even though adverse
outcomes are not limited to women. Men with untreated chlamydial infection can suffer
from complications and continue to transmit infection to their partners. Limiting selective
screening to women misses a sizable proportion of the at-risk population. Testing and
treating men for infection is essential to reducing the spread of disease.
Most current screening criteria recommend STI testing for all sexually active young
people up to age 24 and for anyone reporting risky behaviors. Information specific to young
adults is sparse considering the different epidemiology and barriers to care among teens,
younger, and older adults. As young adults age out of the interval with recommended
universal screening, the more restrictive criteria suggested for older adults may miss a
substantial at-risk population. When examining a representative sample of young people
from the general population, markers of risk or infection status specific to them may be
readily identifiable and incorporated into selective screening criteria directed at young adults.
Factors Associated with Chlamydial Infection among Young Adults
The number of infections identified and the number of tests used determines
adequacy of screening performance (88, 101, 105, 106). To achieve successful selective
screening there must be ways to discriminate between people at high risk and low risk of
infection so that in settings with limited resources testing can be restricted to those at higher
risk. Demographic, behavioral, perceived risk, medical, and health care characteristics can
assist in differentiating across the risk spectrum.
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The available research on asymptomatic young adults in the general population
indicates that not all determinants of STI are consistently important from adolescence
through young adulthood. The effect of young age at first sex on risk of STI diminishes with
age (32). Neither is core group membership constant. Less than one percent of a cohort was
a core group member, defined by number of sex partners, at age 18 and age 21 and age 26.
Salient proportions, though, were core members at one of these ages (107). In the National
Survey of Adolescents Males (NSAM), a greater proportion of participants aged 22 to 26
years, compared to 18 to19 years, tested positive for chlamydial infection (16). These
numbers corroborate national surveillance data showing the highest rate of chlamydial
infection among 20 to 24-year-olds (2). The prevalence of known risk factors also fluctuates
over these ages. The older NSAM participants were more likely to have had unprotected sex,
three or more female partners, or sex with a high-risk partner in the past year (16). Condom
use (108) and STI knowledge also lag with age. A longitudinal assessment of young
women’s understanding of transmission, treatment, and sequelae showed increases between
ages 16 and 18 but then a drop below baseline level at age 23 (109). Young adult men are
less likely than adolescents to receive STI prevention information (110).
Adult risk factors for STI are not all strongly associated with infection in young
people. There is an association between crack cocaine use and STI among adults, but not
adolescents (111). In a cross-sectional study of emergency room patients, different
predictors of gonorrhea or chlamydial infection emerged when analyzing patients aged 18 to
31 years rather than the full population, aged 18 to 44 years (112). Among women aged 18
to 44 years, the largest proportion reporting multiple partners were aged 20 to 29 years (113).
The shifting of risk determinants between adolescence and adulthood may reflect differences
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in high-risk sexual networks. If the early twenties is a period of transition from adolescent to
adult behaviors and lifestyles, there may be a set of risk predictors unique to young adults.
Viable selective screening guidelines for young men and women are lacking for
chlamydial infection, one of the most prevalent, costly, and curable STI. While screening
criteria exist for adolescents and older adults, there are no comparable guidelines for young
adults in the general population. Until now, the unique combination of data necessary to
appropriately develop screening criteria for this population has not existed. Add Health
combines the results of nucleic acid amplification tests for STI with comprehensive
demographic, behavioral, and health care information for a large, representative sample of
US young adults, all of which are essential to the development of usable, effective, and
efficient screening criteria.
Partner Age Difference and Chlamydial Infection
Qualities of sexual partnerships may place one member at elevated risk of STI.
Disparities in risk of chlamydial infection exist across categories of demographic, social, and
behavioral factors. Higher STI rates are associated with specific mixing patterns – sexual
links between members of distinct sexual networks and populations (18, 114). Discordant
race/ethnicity (18), socioeconomic, employment or education status (18, 115), gap length
between relationships (116), concurrency (115, 117-119), lack of monogamy (120), and
partner behavior (18, 39, 121-123) facilitate the spread and maintenance of infection.
Bridging across age also presents a prime opportunity for mixing low and high prevalence
populations (18, 23, 124).
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There is incomplete and conflicting information about the association between age
discordancy and risk of STI. Partner mixing by age is common among both adolescents and
young adults (22, 23). Among adolescents, females involved with older partners are more
likely to have intercourse compared to females involved with partners their own age (28).
When examining STI, rather than intercourse, older partners are not associated with repeat
infection among adolescent females diagnosed with chlamydial infection (125). Among
pregnant adolescents, however, those with older partners are four times more likely to test
positive for chlamydial infection and twice as likely to report that their partner is not
monogamous (24). Two studies reporting the effect of partner age difference on STI among
adults found little association with older partners, but one study diagnosed chlamydial
infection by culture (18) and the other relied on self-report of STI test or treatment in the past
year (23). It is unclear whether age discordancy is truly a determinant of increased risk, and
whether there is an age at which discordancy ceases to be an important factor.
Methodological issues such as the magnitude of age difference, shifting importance of
differences across ages, and choice of study population may account for some of the
discrepant findings (126). An additional factor to consider is that most studies examine the
association of STI and main partner only, when the age difference between non-main
partners may be more suggestive of increased risk (126).
Conclusions
Sexually transmitted infections are an enormous public health burden, especially
among young people. The long term effects of untreated or inadequately treated STI may
reach beyond adolescence into adulthood, and the economic and personal costs may continue
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over a lifetime. Screening is fundamental to reducing infection prevalence, yet population-
based screening guidelines specific to young adults are lacking for both women and men.
Analysis of the Add Health project can deliver these screening guidelines and fill this basic
gap in STI prevention. Additionally, even though STI has been researched extensively,
important questions about infection epidemiology, particularly among young adults, remain
unanswered. A deeper understanding of the association of partner age difference with
infection among young women may contribute greatly to reducing the incidence and
prevalence of sexually transmitted infection.
CHAPTER 3
RESEARCH DESIGN AND METHODS
Overview of Study Design and Population
Wave I of the Add Health Study included questionnaires administered to individual
participants, their parents, school peers, and school administrators. Wave II repeated similar
questionnaires for the individual participants and updates from school administrators. Wave
I and II field work was conducted by the National Opinion Research Center of the University
of Chicago. The Wave I and II questionnaires administered to the individual participants
were extensive. The questionnaires included 39 sections covering demographics, daily
activities, romantic partnerships, sexual activity, contraceptive use, health care utilization,
and risk taking behaviors. Wave III field work was conducted by the Research Triangle
Institute. The Wave III questionnaire was updated to obtain relationship, marital,
childbearing, educational, and employment histories as well as collecting biological
specimens and interviewing a sample of heterosexual partners of respondents. An
interviewer traveled to the participant’s home or other suitable location identified by the
potential participant. After obtaining written consent, interviewers conducted the
approximately 90-minute session in as private an area as possible. For non-sensitive issues,
the interviewer recorded responses directly into a laptop computer. For sensitive issues,
computer-assisted self-interview (CASI) allowed the participant to enter responses
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directly into the computer. The use of CASI tends to increase the frequency of responses for
sensitive issues (127-131).
Add Health used a two-stage sampling scheme with over sampling of particular
groups. The primary sampling frame for the original Add Health sample included all high
schools in the US with an 11th grade and at least 30 students in the school. Feeder middle
schools – schools that included a seventh grade and sent at least five graduates to a high
school – were identified by the high school and selected with a probability proportional to the
number of students continuing on to the high school. From this sampling frame, a systematic
random sample of 80 high schools and 52 middle schools was chosen with unequal
probability of selection. The sampling of schools was stratified into 80 clusters to ensure that
the schools were representative of US schools with respect to key demographic features
(Table 3.1). Over 70% of the originally sampled high schools participated.
Table 3.1 Add Health School Sampling Scheme
Characteristic Categorizations
region northeast midwest south west
urbanicity urban suburban rural
school size 125 or fewer 126 – 350 351 – 775 776 or greater
school type public private parochial
percent white 0 1 – 66 67 – 93 94 – 100
percent black 0 1 – 6 7 – 33 34 – 100
grade span K – 12 7 – 12 9 – 12 10 – 12
curriculum general vocational alternative special education
The original study participants were identified from rosters of students in grades
seven through 12 enrolled in the selected schools early in the 1994 to 1995 school year.
90,118 students and 164 school administrators completed self-administered, in-school
questionnaires. Students in each school were stratified by grade and sex for selection into the
in-home core sample. About 17 students were randomly chosen from each stratum so that a
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total of approximately 200 adolescents were selected from each of the 80 school clusters.
These 12,105 students comprised the core sample.
Special oversamples were also selected to complement the core sample. Oversample
eligibility was determined by student response to the in-school questionnaire. Adolescents
could qualify for more than one sample. Black students with a college-educated parent (n =
1,038), Chinese (n = 334), Cuban (n = 450), and Puerto Rican (n = 437) students were
oversampled to increase the precision of the estimates for these groups. Other special
subsamples included saturated schools, persons with disabilities, and genetic samples. In 16
schools, all enrolled students were selected for in-home interviews to facilitate social
network analysis (n = 2,553). This saturation sample included two large schools – one
predominantly white and located in a mid-sized town and the other ethnically heterogeneous
and located in a major metropolitan area – and 14 small schools. The disability sample was
for adolescents self-reporting a physical limb disability (n = 471). Lastly, various sibling
pairs living in the same household (n = 4,527) were invited to participate to construct a
genetic sample database. In total, 20,745 adolescents and 17,700 parents completed Wave I
in-home interviews.
Wave II data collection included 128 follow-up school administrator questionnaires
and 14,738 adolescent in-home interviews. The Wave II in-home interview sample was the
same as the Wave I in-home interview sample except that 1) respondents who were in the
12th grade at Wave I and who were not part of the genetic sample were not interviewed at
Wave II; 2) respondents who were only in the Wave I disabled sample were not re-
interviewed; and 3) 65 adolescents who were members of the genetic sample but had not
been interviewed at Wave I were recruited at Wave II.
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Wave III targeted all original Wave I participants currently living in the continental
US, Alaska, or Hawaii, including military personnel stationed domestically and participants
in detention facilities. Data collection covered 15,197 in-home interviews, 1,507 interviews
with partners of respondents, and collection of biological specimens. Post-stratification
sampling weights were calculated to account for persons who could not be located or refused
to participate. With these sampling weights, accounting for the school as the primary
sampling unit and using region of the country as a stratification variable, the Add Health
Wave III cohort provides a representative sample of young adults aged 18 to 26 years living
in the US. All participants with sample weights who reported at the Wave III interview ever
having vaginal intercourse, and who had usable chlamydia test results, were included in the
analyses.
Data Collection and Measurement
With the exception of laboratory-confirmed STI in Wave III and physical
measurements for height and weight, all data collected throughout the Add Health project
were self-reported. Certain family-level details from Wave I, such as family composition
and socioeconomic status were gathered from both student and parent.
All Wave III original respondents and a sample of recruited partners aged 18 years or
older were asked to provide a urine specimen to test for Chlamydia trachomatis (132).
Before the start of each session, the interviewer described the Wave III interview, obtained
consent for participation, and informed respondents that at the end of the interview they
would be asked to provide urine specimens for STI testing. At the end of the interview,
respondents were asked to consent to and provide a urine specimen for STI testing. Those
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providing a urine specimen received $10. Respondents providing the specimen were given a
toll-free telephone number and secure procedures to obtain counseling and their confidential
test results, the toll-free telephone number for CDC’s National STD and AIDS Hotline, and
information about chlamydia and other sexually transmitted infections. Participants were
also informed that they were not being tested for all STI and should not view their
participation in Add Health as a substitute for health care. Results of these assays were not
reported to local public health departments based on the terms of a Certificate of
Confidentiality obtained from the US Department of Health and Human Services.
Urine specimens were tested for Chlamydia trachomatis per manufacturer
instructions using ligase chain reaction (LCR™) amplification technology in the Abbott
LCx® Probe System (Abbott Laboratories, Abbott Park, IL). Urine specimens were
collected in a 30ml cup with a line marked at 15ml. Specimens were immediately cooled to
2 – 8 degrees Celsius inside a cooler with ice packs. The LCR assay required 15 – 20ml of
first stream urine collected in a plastic, preservative-free, sterile urine specimen cup from
respondents who had not urinated within one hour prior to collection. Respondents received
instructions about collection procedures from interviewers who had extensive training,
including training by Abbott Laboratory representatives. If respondents asked to be excused
to urinate before the end of the interview, consent and specimen collection occurred at that
time to avoid situations where the respondents would be ineligible to provide a specimen at
the end of the interview because of voiding within the previous hour. Cooled urine
specimens were packaged and overnight expressed to arrive for diagnostic testing at the
University of North Carolina at Chapel Hill by the next morning. Samples were received in
the laboratory within four days of collection. Upon arrival, urine specimens were inspected
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for adherence to appropriate shipping conditions, including the presence of the appropriate
bar code label, date and time of collection, temperature on arrival, and volume of urine. All
urine samples were processed on the day of arrival by trained laboratory technologists.
C. trachomatis was identified in urine specimens by LCR assay. LCR assays were
performed according to the manufacturer’s instructions, except that specimens exceeding the
recommended volume of 20ml were tested. The testing laboratory performed sample
processing in a dedicated pre-amplification area that was monitored routinely for
contamination by wipe testing. An open vial was maintained on the bench top and then
carried through sample processing to monitor contamination. A laboratory-prepared positive
control was also processed with each run as an external monitor of sample processing and
detection. The post-amplification area, including instrumentation, was monitored by wipe
testing in a fashion similar to the pre-amplification area. Routine instrumentation monitoring
and preventive maintenance were performed per the manufacturer’s recommendations. The
LCR results were reviewed for acceptability by the responsible technologist as well as a
second individual. Ligase chain reaction results were expressed as a signal to cutoff ratio
determined by relating the sample rate for each specimen to the cutoff value of assay
calibrator duplicates. The Abbott analyzer automatically performed these calculations. All
samples with a signal to cutoff ratio of at least 0.80 were retested to reduce the potential for
false-positive test results. Retested samples with a signal to cutoff ratio of at least 1.00 were
considered positive.
All test results were entered into a database by an individual technologist who used a
bar code scanner to ensure accurate result-sample identification. Two additional reviewers
verified the computer entry.
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Statistical Methods Aim One
Selective Screening Guidelines for Chlamydial Infection in US Young Adults
The Aim One objective was to develop criteria for screening young women and men
in the US general population for prevalent chlamydial infection. The outcome of interest was
a positive C. trachomatis test result. Analyses were performed separately by gender to
accommodate sex-specific differences in predictors of STI and prevalence of chlamydial
infection (111, 133-135). Candidate variables were identified from the literature and by their
biologic or environmental plausibility of predicting infection with chlamydia. Numerous
candidate predictor characteristics were derived from the self-reported demographic,
behavior, perceived risk, and health care factors available from the in-home interview (Table
3.2). Variable derivation schemes are detailed in Appendix Two
Table 3.2 Candidate Variables for Screening Criteria
Demographic Behavioral Perceived Risk Medical/Health Care
age, years age at sexual debut STD STD-like symptoms
race/ethnicity number of partners HIV tested for STD, past year
partner race/ethnicity sexuality prior STD
region condom use insurance status
marital status recent health care use
shared housing forgone care, past year
student status antibiotic use, past 30 days
high school graduate hormonal contraception
military history pregnancy history
employment status
functional poverty
Initial analysis included frequency distributions of all covariates. The frequencies
were tabulated for categorical and graphed for continuous variables. Candidate variables
were eliminated if there were excessive missing data or the distribution was too narrow to be
meaningfully predictive. We transformed continuous variables to quadratic or cubic splines
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and assessed their fit. Continuous and multilevel categorical variables were evaluated for
linearity in the logit by plotting the logits and examining the incremental odds ratios of the
covariate–outcome association. Variables that did not meet this assumption were categorized
using indicator variables. Collinearity was measured using standard techniques, including
magnitude of the bivariate odds ratio, correlation coefficient, variable inflation factor,
likelihood ratio tests, and Hosmer-Lemeshow goodness of fit statistics (136, 137). Highly
correlated variables were recoded or only one variable was selected for use based on
substantive meaning and the relation among variables.
Predictive models were developed using multiple logistic regression. Other modeling
strategies, such as multiple additive regression tree models, can be beneficial for predicting
outcomes, but logistic regression remains the preferred method for clinical use. The
improvement in predictive power attained through alternative modeling methods is offset by
logistic regression’s ability to accommodate sample weighting from complex survey designs.
The reliability of a logistic predictive model is a function of the prevalence of the
outcome in the study population, the total study population, the number of variables fitted in
the model, and how well the variables have been measured. To estimate the maximum
number of variables practical for a model, we used the formula [(3*n1*n2)/N]/10 where n1 is
the number of persons with the outcome, n2 is the number of persons without the outcome,
and N is the total population (138). In this community-based sample of approximately 5,800
women and 5,000 men with usable test results, the prevalence of chlamydial infection was
five percent and four percent, respectively. Over 50 variables could be included in the
regression models for women and men.
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Analysis was performed using Stata Version 7.0 (Stata Corporation, College Station,
TX). Evaluation of model fit and bootstrap estimates were obtained from unweighted data.
All other analyses accounted for Add Health’s complex survey design by using school as the
primary sampling unit, region of the country as the stratification variable, and post-
stratification weights. In preliminary analyses, we examined the frequency distribution of the
potential predictor characteristics and calculated bivariate prevalence odds ratios (OR) and
95 percent confidence intervals (CI) to assess the association between each characteristic and
chlamydial infection.
For each gender, we developed three separate predictive models using either 1) the
respondent’s race/ethnicity; or 2) the respondent’s most recent partner’s race/ethnicity; or 3)
no information on race/ethnicity. The initial starting models included one of the
race/ethnicity components and all variables with bivariate p<0.25. We used a high alpha
level because bivariate analyses can lead to exclusion of important variables in the
multivariate setting (139). Variables with excessive missing data, extreme collinearity, or
uninformative distributions were excluded from the starting model regardless of p-value.
Each model included only those respondents with complete information on all variables in
that full model.
Predictive model development used unconditional multiple logistic regression for
survey data with a backwards elimination strategy (138). Variables were removed one at a
time from the model, beginning with the variable with the largest p-value. The model-based
c-statistic, the area under the receiver operating characteristic (ROC) curve, was compared
between each successive model to ensure that variable removal did not adversely affect
model performance. A change in area under the ROC curve<0.01 was acceptable.
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Backwards elimination stopped when all remaining variables had p<0.05. We examined the
models for collinearity and overly influential covariate patterns (136).
We created three sets of clinical risk scores from each final model. The first was the
predicted probability of infection based on the logistic model. The second was a weighted
risk score calculated by multiplying the regression coefficients by two and rounding to the
nearest integer. The third was an unweighted risk score that assigned each risk category a
value of one, regardless of its strength of association with infection, and each reference
category a value of zero. Sensitivity and specificity of each predictive model and its
corresponding risk scores were assessed at three hypothetical program driven cutoffs based
on a maximum percentage of the screened population (70%, 50%, 30%) to receive a
diagnostic test. In settings with limited resources, the absolute number of tests (a function of
the funds available) and the prevalence of infection in the population can aid cutoff selection
(101). We validated risk score performance using 1,000 bootstrap samples with replacement
(138), although this technique could not accommodate Add Health’s complex survey design.
Statistical Methods Aim Two
Partner Age Difference and Chlamydial Infection among Young Adult Women
The Aim Two objective was to assess the association between partner age difference
and prevalent chlamydial infection among young adult women. The outcome of interest was
a positive C. trachomatis test result. The primary exposure measure was the difference in
years between each female study participant and her most recent male sex partner. The
woman reported her partner’s age. A negative age difference meant the woman’s partner
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was younger. A positive age difference meant the woman’s partner was older. Additionally,
as a secondary exposure, we used the age difference of the most age-discordant partner in the
past year. The exposure measures were categorized to reflect substantively meaningful age
differences. Potential modifying or confounding variables were derived from the self-
reported demographic, behavior, and health care factors available from the in-home interview
(Table 3.3). Variable derivation schemes are detailed in Appendix Two.
Table 3.3 Candidate Effect Measure Modifiers or Confounders
Demographic Behavioral Medical/Health Care
age, years age at first sex antibiotic use, past 30 days
race/ethnicity number of partners, past year
marital status condom use
employment status exchange sex for drugs or money
functional poverty regret sex, past year
education
Initial analysis included frequency distributions of all covariates. The frequencies
were tabulated for categorical and graphed for continuous variables. Candidate variables
were eliminated if there were excessive missing data. We transformed continuous variables
to quadratic or cubic splines and assessed their fit. Continuous and multilevel categorical
variables were evaluated for linearity in the logit by plotting the logits and examining the
incremental odds ratios of the covariate–outcome association. Variables that did not meet
this assumption were categorized using indicator variables. Collinearity was measured using
standard techniques, including magnitude of bivariate odds ratio, correlation coefficient,
variable inflation factor, likelihood ratio tests, and Hosmer-Lemeshow goodness of fit
statistics (136, 137). Highly correlated variables were recoded or only one variable was
selected for use based on substantive meaning and the relation among variables.
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Interaction terms between the exposures and age, race/ethnicity, and number of sex
partners in the past year were created to test for effect measure modification. If the modeled
interaction term was significant (p<0.15) and the stratified odds ratios were substantively
different from the unstratified measures, the interaction term was retained in the model.
Potential for confounding was appraised through modeled bivariate odds ratios to
allow for sample weighting. The bivariate distribution of each covariate among all subjects
and the outcome by each covariate conditional on non-exposure (partner age within one year
of woman’s age) was checked for strength of association to help identify which variables met
the confounding criteria (140) and may be candidates for adjustment during the multiple
regression modeling process.
Analysis was performed using Stata Version 7.0 (Stata Corporation, College Station,
TX). Analyses accounted for Add Health’s complex survey design by using school as the
primary sampling unit, region of the country as the stratification variable, and post-
stratification weights. In preliminary analyses, we examined the frequency distribution of the
outcome, primary and secondary exposures, and other covariates. We calculated bivariate
prevalence odds ratios and 95 percent confidence intervals to assess the relationship between
the covariates and chlamydial infection.
Mixing by age within a partnership can be assortative (like-with-like), disassortative
(like-with-unlike), or random. The Q statistic, defined as ( iwi – 1)/(N – 1) where wi is the
matrix eigen value, uses an N*N mixing matrix to identify high or low within-group mixing
(114, 141). For these analyses, the matrix rows were the categorized age of the woman and
the matrix columns were the categorized age of the male partner, calculated for the two
partner age difference measures. This assessment could not incorporate survey weighting.
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Model development used unconditional multiple logistic regression for survey data
with a backwards elimination strategy (142). Covariates that could potentially modify or
confound the association between age difference and prevalent chlamydial infection were
included in the full model. We tested the null hypothesis that interaction terms between the
exposure and each potential modifier were equal to zero, and looked for substantive changes
between unstratified and stratified effect estimates. After examination and removal of
interaction terms, we eliminated potentially confounding covariates one at a time from the
model beginning with the variable with the largest p-value. We evaluated confounding by
comparing the crude, adjusted, and fully adjusted effect estimates. We retained the covariate
if the change in estimates was greater than 10 percent (143). Otherwise, the covariate was
dropped. Backwards elimination stopped when all covariates that neither modified nor
confounded the association between age difference and chlamydial infection were
eliminated. We examined the final model for collinearity and overly influential covariate
patterns. Primary and secondary exposure measures were evaluated through separate but
identical processes.
CHAPTER 4
RESULTS AIM ONE: COMMUNITY-BASED SELECTIVE SCREENING GUIDELINES
FOR PREVALENT CHLAMYDIAL INFECTION IN US YOUNG ADULTS
Chlamydia trachomatis, with an estimated three million new infections each year, is
the most common bacterial sexually transmitted infection (STI) in the United States (US),
especially among adolescents and young adults (1). Black, Native American, and Latino
women and men are disproportionately burdened with infection (2). Chlamydial infection
may cause pelvic inflammatory disease, ectopic pregnancy, and tubal infertility in women (4-
6). Infection increases susceptibility to and transmission of HIV in women and men (8, 9).
This STI causes substantial morbidity, but it can be detected with a urine-based nucleic acid
amplification test and cured by a single dose of oral antibiotics.
Testing and treatment for chlamydial infection is challenging because infections are
asymptomatic in approximately 70 percent of women and 50 percent of men (10). The US
Preventive Services Task Force “strongly recommends” that clinicians routinely screen all
sexually active women aged 25 years or younger for chlamydial infection (14). However,
screening rates remain remarkably low (12, 13), despite the inclusion of chlamydial
screening in the Health Plan Employer Data and Information Set (HEDIS) performance
measures (11). Furthermore, chlamydial infection in men is not addressed by current
recommendations.
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Programs to expand testing to community settings may increase screening rates.
Community-based testing is a potentially valuable way to reach young adults in the general
population with asymptomatic infection. Selective screening criteria to identify for testing
individuals at greatest risk of infection may be necessary to make such programs logistically
and economically feasible (144, 145). Guidelines to be used in community settings should be
based on data from the general population, rather than algorithms derived from clinical
settings. Wave III of the National Longitudinal Study of Adolescent Health (Add Health)
was used to develop criteria for screening young women and men in the US general
population for prevalent chlamydial infection.
MATERIALS AND METHODS
Study design and sample
Add Health is a prospective cohort study that has followed nearly 20,000 adolescents
into adulthood over three waves of data collection (146). For this study, we conducted a
cross-sectional analysis of Wave III (April 2, 2001 to May 9, 2002), which targeted all Wave
I participants. Our study population was restricted to Wave III participants responding “Yes”
when asked “Have you ever had vaginal intercourse?” The University of North Carolina
institutional review board approved all study procedures.
The two-stage sampling of Add Health has been described in detail elsewhere (146,
147). Briefly, a systematic random sample of secondary schools was chosen with unequal
probability of selection and stratified to ensure that the schools were representative of all US
secondary schools with respect to key characteristics. The original participants were
identified from students in grades seven through 12 enrolled in the schools. This core sample
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was complemented by oversampling some black and Latino students to enhance the precision
of estimates for these groups. Post-stratification sampling weights adjust for persons who did
not participate in Wave III. After accounting for design effect, the Add Health Wave III
cohort provides a representative sample of young adults aged 18 to 26 years living in the US.
Interview and specimen collection
For non-sensitive issues, the interviewer recorded responses into a computer. For
sensitive issues like sexual behaviors, the participant used computer-assisted self-interview
(CASI) to enter the responses directly into the computer.
Respondents were asked to provide a urine specimen to test for Chlamydia
trachomatis, for which they received $10. A more detailed description of Add Health STI
testing is available elsewhere (132). Specimens were tested for C. trachomatis per
manufacturer instructions using ligase chain reaction (LCR™) amplification technology in
the Abbott LCx® Probe System (Abbott Laboratories, Abbott Park, IL), except that
specimens exceeding the recommended volume of 20ml were tested.
Measures
The outcome variable was a positive C. trachomatis test result. Possible predictor
variables were derived from the self-reported demographic, behavior, perceived risk, and
health care factors available from the in-home interview.
Statistical analyses
We conducted analyses using Stata Version 7.0 (Stata Corporation, College Station,
TX). Evaluation of model fit and bootstrap estimates were obtained from unweighted data.
All other analyses accounted for Add Health’s complex survey design by using school as the
primary sampling unit, region of the country as the stratification variable, and post-
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stratification weights. Analyses were performed separately by gender to accommodate sex-
specific differences in predictors of STI and prevalence of chlamydial infection (111, 133-
135). In preliminary analyses, we examined the frequency distribution of potential predictor
characteristics and calculated bivariate prevalence odds ratios (OR) and 95 percent
confidence intervals (CI) to assess the association between each characteristic and
chlamydial infection.
For each gender, we developed three separate predictive models using either 1) the
respondent’s race/ethnicity; or 2) the respondent’s most recent partner’s race/ethnicity; or 3)
no information on respondent’s or partner’s race/ethnicity. The initial starting models
included one of the race/ethnicity components and all variables with bivariate p<0.25.
Variables with excessive missing data, extreme collinearity, or uninformative distributions
were excluded from the starting models, regardless of p-value. Each model included only
those respondents with complete information on all variables in that full model.
Predictive model development used unconditional multiple logistic regression for
survey data with a backwards elimination strategy (138). Variables were removed one at a
time from the model, beginning with the variable with the largest p-value. The model-based
c-statistic, the area under the receiver operating characteristic (ROC) curve, was compared
between each successive model to ensure that variable removal did not adversely affect
model performance. A change in area under the ROC curve<0.01 was acceptable.
Backwards elimination stopped when all remaining variables had p<0.05. We examined the
models for collinearity and overly influential covariate patterns (136).
We created three sets of clinical risk scores from each final model. The first was
based on the predicted probability of infection. The second was a weighted risk score
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calculated by multiplying the regression coefficients by two and rounding to the nearest
integer. The third was an unweighted risk score that assigned each risk category a value of
one, regardless of its strength of association with infection, and each reference category a
value of zero. Sensitivity and specificity of each predictive model and its risk scores were
assessed at three hypothetical program driven cutoffs based on a maximum percentage of the
population (70, 50, 30) to receive a diagnostic test. We validated model and risk score
performance using 1,000 bootstrap samples with replacement (138), although this technique
could not accommodate Add Health’s complex survey design.
RESULTS
Study population
Of the 18,924 Add Health participants in the nationally representative Wave I sample,
1,109 (5.9%) refused participation, 3,493 (18.5%) could not be located or were unable to
participate, and 14,322 (75.7%) were located and agreed to participate in Wave III. Of these,
12,334 (86.1%) reported ever having vaginal intercourse. C. trachomatis results were
available for 10,928 (88.6%) of the sexually experienced participants. Reasons for
unavailable test results included inability or refusal to provide a urine specimen, processing
errors due to shipping, or laboratory problems.
Among participants with chlamydia test results, 50.0 percent of the study sample was
women (Table 4.1). The majority (67.8%) was white, with representation of black (16.7%),
Latino (11.5%), Asian American (3.2%), and Native American (0.8%) participants. The
mean age of participants was 21.9 years (standard error (SE), 0.12 years). The mean age at
sexual debut was 16.4 years (SE, 0.06 years) and the mean number of sex partners during the
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past year was 1.8 partners (SE, 0.03 partners). On average, women had fewer partners (1.5
partners, SE 0.04) than men (2.0 partners, SE 0.06).
Females
Bivariate analyses. The overall prevalence of chlamydial infection among sexually
experienced women was 5.1 percent (95% CI 4.2%, 6.0%). Women who were black (OR
5.7, 95% CI 3.9, 8.5) or Native American (OR 6.1, 95% CI 2.3, 16.1) were more likely to
have chlamydial infection as compared to whites (Table 4.2). Women reporting black
partners (OR 6.9, 95% CI 4.5, 10.6) also were more likely to have chlamydial infection.
When compared to women with no sex partners in the past year, the relation between number
of partners and infection was nearly twice as strong for two or more sex partners (OR 7.4,
95% CI 2.8, 19.2) than for one partner (OR 3.4, 95% CI 1.4, 8.5). While a moderate or high
perceived risk of STI (OR 5.5, 95% CI 3.1, 9.8) was indicative of infection, neither STI
symptoms within the past 24 hours (OR 1.0, 95% CI 0.6, 1.8) nor STI symptoms (OR 1.0,
95% CI 0.7, 1.4), test (OR 1.1, 95% CI 0.8, 1.5), or diagnosis (OR 1.6, 95% CI 1.0, 2.4)
within the past year, showed substantive association with prevalent chlamydial infection.
Multivariate analyses. We constructed three reference models for women that
included the race/ethnicity component (respondent’s race, partner’s race, or no race) and 17
characteristics with bivariate p<0.25. After removing variables that minimally predicted
chlamydial infection, number of partners, perceived risk of STI, and student status
consistently remained important across the three final models (Table 4.3a). The final models
with respondent race (area under ROC curve=0.77) and partner race (area under ROC
curve=0.75) information performed comparably and both were substantially better than the
model without race information (area under ROC curve=0.70; p <0.001; Figure 4.1a).
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Risk Scores. The weighted risk scores for model with respondent race information
ranged from zero for a white woman, with no sex partners in the past year, low perceived risk
of STI, who was a student, aged 22 – 24 years, to a score of 13 for a Native American
woman, with two or more sex partners in the past year, moderate or high perceived risk of
STI, not a student, and was either younger than age 22 or older than age 24 years (Table
4.3a). Using the weighted risk score to identify no more than 50 percent of the population
for testing, the sensitivity of the model with respondent race information (84.1%) was
slightly higher than the model with partner race information (81.3%), but substantially higher
than the model with no race information (60.1%; Table 4.4a).
While the sensitivity and specificity of the three models are comparable at several
cutoffs, the models’ performance is strikingly different when stratified by race (Table 4.5a).
The most sensitive screening for white women uses the predicted probability from the model
with no race information (72.5%). Among black women, however, the sensitivities of the
models with respondent and partner race information are nearly all above 90 percent and the
no race model performs poorly. Testing 50 percent using the weighted risk score for the
model with no race information is 61.8 percent sensitive among black women, compared to
99.4 percent in the model with race and 94.7 percent in the model with partner race
information. The situation for women of other races parallels that of black women.
To illustrate the impact of the differing sensitivities across the three models, we
examined the estimated number of infections correctly identified in the general population of
women aged 18 to 26 years (Table 4.6a). The race information model weighted risk score
could correctly identify 142,350 out of 142,776 infections among black women. The no race
information model would miss more than 50,000 of these infections. Among white women,
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the number of missed infections between the models with and without race information is
fewer than 10,000. The number of women without infection who were identified for testing
(i.e. false positives) is substantial, regardless of the model.
Males
Bivariate analyses. The overall prevalence of chlamydial infection among sexually
experienced men was 3.9 percent (95% CI 3.1%, 4.8%). Men who were black (OR 8.0, 95%
CI 4.9, 13.1), Native American (OR 5.7, 95% CI 2.1, 15.6), or Latino (OR 5.3, 95% CI 2.9,
9.9) were more likely to have chlamydial infection as compared to whites. Men reporting
black (OR 5.9, 95% CI 3.4, 10.4) or Latino (OR 3.5, 95% CI 1.6, 7.8) partners were also
more likely to have chlamydial infection (Table 4.2). Similar to women, a moderate or high
perceived risk of STI (OR 5.2, 95% CI 2.6, 10.4) was indicative of infection. Unlike women,
STI symptoms (OR 2.4, 95% CI 1.5, 3.8) or diagnosis (OR 2.6, 95% CI 1.4, 5.0) within the
past year as well as no recent antibiotic use (OR 2.9, 95% CI 1.4, 6.2) and shared housing
(OR 2.3, 95% CI 1.5, 3.7) were linked to prevalent chlamydial infection.
Multivariate analyses. We constructed three reference models for men that included
the race/ethnicity component and 16 characteristics with bivariate p<0.25. A core set of
characteristics – perceived risk of STI, military history, shared housing, and high school
degree – remained important in all three models (Table 4.3b). The final models with
respondent race (area under ROC curve=0.74) and partner race (area under ROC curve=0.75)
information were comparable, and superior to the model without race information (area
under ROC curve=0.69; p=0.02; Figure 4.1b).
Risk scores. The weighted risk scores for the model with respondent race information
ranged from zero for a white man, with low perceived risk of STI, no military history, lived
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alone, had graduated from high school, and accessed health care within the past year, to 12
for a black man, with moderate or high perceived risk of STI, military experience, shared
housing, who was not a high school graduate, and had not recently accessed health care
(Table 4.3b). Using a weighted score to test 50 percent of those screened by the respondent
race information model yielded a sensitivity of 82.5 percent and specificity of 55.3 percent
(Table 4.4b).
The difference in model performance among white, black, and other respondents is
again prominent (Table 4.5b). Testing 50 percent with a weighted risk score is 100 percent
sensitive among black men with the respondent race information model, but only 71.4
percent sensitive with the no race information model. The models performed poorly for
white men, with the no race information model yielding the highest sensitivity (58.7%) and
the respondent race information model the lowest sensitivity (33.7%).
Using the survey weights to estimate the number of infections correctly identified in
the general population of men aged 18 to 26 years, the weighted risk score for the model with
race information would correctly identify all 80,756 infections among black men (Table
4.6b). The model with no race information would identify only 54,152 of these infections.
Again, the number of men tested who do not have chlamydial infection is large.
Confidence intervals derived from bootstrap validation were consistent with all
findings for women and men.
DISCUSSION
Testing and treatment for chlamydial infection can lower the prevalence of infection
(56, 57, 59) and the incidence of pelvic inflammatory disease (58). Still, young people
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remain unaware of asymptomatic STI and the need for screening (53). Current guidelines
recommend annual universal testing of sexually active young women for chlamydial
infection (14, 81), but only an estimated 55 – 66 percent of females aged 15 – 19 were
screened in 2000 (12). Self-report of STI testing is even lower (13). One reason for low
screening rates may be that these guidelines require women to visit health care providers.
Community-based screening may expand screening coverage among young people, including
men, who are often uninsured and unlikely to access health care regularly (148-150).
Our proposed screening criteria differ from earlier criteria because they were
developed from a representative sample of the population they are designed to serve.
Additionally, the guidelines are available for women and men. A combination of five
characteristics for women (race/ethnicity, number of sex partners in the past year, perceived
risk of STI, student status, and age) and six characteristics for men (race/ethnicity, perceived
risk of STI, military history, shared housing, education level, and recent health care use)
provide potentially useful screening tools, although implementation of these criteria may be
problematic because of the inclusion of race-related information. Applying these criteria to
select no more than 50 percent of the population for diagnostic testing would identify
approximately 80 percent of infections in women and men. Many uninfected people would
be tested, but there is no evidence of durable distress or harm after population screening for
chlamydial infection (151). Also, the number of uninfected people tested would be lower
than the number that would be tested under current universal screening guidelines.
Add Health provides the most comprehensive assessment to date of chlamydial
infection and related risk factors in US young adults. It reinforces previous findings of
marked differences in infection prevalence across racial/ethnic groups, with black and Native
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American females and black, Latino, and Native American males, more likely to have a
prevalent chlamydial infection than their white counterparts. The Add Health design ensured
that estimated effects would be independent of reporting by clinicians and health care
seeking behavior – common explanations for racial and ethnic differences evident in reported
infection rates. Furthermore, the oversampling of black and Latino groups enhanced the
precision of these estimates.
The two models developed with race/ethnicity information were similar in both
constituent characteristics and overall performance because of the strong correlation between
a respondent’s and partner’s race/ethnicity. In contrast, the performance of the model
developed without information on race/ethnicity was greatly diminished for everyone except
white women and men. Despite the inclusion of numerous covariates at the outset, no proxy
for socioeconomic status or other connection to elevated prevalence remained in the final
models. Detailed data on sexual networks or environmental characteristics that may address
the disparity in infection prevalence were unavailable in these data and would not be
typically available for use in routine screening settings.
Ideally, screening guidelines would identify individuals for testing based solely on
risk behaviors. Risk stratification appears to differ by race/ethnicity (152). Chlamydial
infection is increased among white young adults with traditional risk behaviors, but black
young adults are at high risk of chlamydial infection even when practicing behaviors that are
low risk for white youth (152). This observation may explain why the model without
race/ethnicity information performed poorly among non-white subpopulations.
The use of race/ethnicity in any STI screening algorithm is undoubtedly controversial,
and may have significant consequences. Stigmatization and perpetuation of inappropriate
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and incorrect stereotypes may result. Using the model with a race/ethnicity criterion ignores
both contemporary and historical context and may further marginalize minority communities.
It is essential, though, to recognize the potential damage from excluding race-related
information. Exclusion of race-related information identified markedly fewer infections,
especially among the minority populations with the highest prevalence. Consequently, if
selective screening was implemented ignoring the race/ethnicity information, many minority
young adults would go untested and untreated, thus perpetuating the high prevalence status
quo. Although many would dismiss outright the inclusion of race-related information in STI
screening guidelines, the true public health costs of this decision must be considered.
Universal screening, while financially expensive, is socially desirable. Ensuring truly
universal screening for chlamydial infection would avoid the stigma of guidelines
incorporating race/ethnicity, but must be considered in the prevailing context of unequal
access to testing, treatment, and counseling.
Our study, like all studies using STI measures, is limited by the adequacy of the study
sample and the characteristics of the diagnostic test used. The validity of our results depends
on the representativeness of the original school-based sample, nonresponse to the Wave III
follow-up survey, truthful reporting on sexual experience, and refusal or other problems that
led to a missing outcome. The original sample included only students on school registers,
but an evaluation of school dropouts suggests any resultant bias in Add Health is small (153).
Poststratification sample weight adjustment accounted for the 24 percent of Wave I
participants who could not be located for Wave III, a bias that was also small (154). Both the
frequency and validity of responses to sensitive questions about sexual experiences were
likely improved through the use of CASI (127-131). Additionally, participants who did and
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did not provide urine specimens for STI testing were similar (155). Earlier analyses show
prevalence estimates were robust to differences in characteristics of non-respondents and
diagnostic test performance (3).
Undoubtedly messages about risky sexual behaviors and their link to STI are being
communicated, given the strong association between some young adults’ perceived risk of
current STI and diagnosis with prevalent chlamydial infection. However, even with
knowledge of what comprises risk behaviors, young adults in the US continue to be at high
risk of chlamydial infection. Broadening screening programs beyond clinic settings, in
conjunction with continued efforts focused on behavioral change, may reduce the STI burden
among young people. The value of screening programs for men must also be considered
carefully. Given the potential consequences of selectively screening, universal screening
should be implemented where possible. Great care must be taken when addressing
racial/ethnic disparities in infection prevalence. The performance of these selective
screening guidelines, which require neither medical nor laboratory information to identify
individuals for urine-based diagnostic testing, supports the practicality of community-based
chlamydial screening for women and men. Local measures of infection prevalence and
extent of resources can inform the choice of a testing cutoff specialized to each screening
program. Locally relevant information will also be critical for determining whether the use
of race/ethnicity is appropriate to improve the guidelines’ performance. In time, if testing
can be expanded to additional venues, screening rates may increase. With greater screening
coverage, and treatment for the infected, the incidence and prevalence of chlamydial
infection in young people, and the sequelae manifest throughout adulthood, will likely
diminish.
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Table 4.1 Characteristics of Sexually Experienced Respondents with Chlamydia trachomatis
Test Results by Gender, National Longitudinal Study of Adolescent Health, 2001 – 2002
Females (n=5854) Males (n=5074)
Characteristic Number of
Participants
Weighted
Percent
Number of
Participants
Weighted
Percent
Chlamydial infection
Positive 316 5.1 236 3.9
Negative 5538 94.9 4838 96.1
Race/ethnicity
White 3178 68.2 2770 67.5
Black 1364 17.1 1033 16.3
Latino 909 11.0 864 11.9
Asian American 337 2.9 343 3.4
Native American 53 0.8 50 0.9
Partner race/ethnicity
White 2534 62.0 2285 66.0
Black 1192 19.6 6387 13.0
Latino 739 11.1 595 12.3
Other 427 7.2 446 8.7
Region
South 2216 38.8 1897 40.4
Outside South 3537 61.2 3101 59.6
Age, years
18 – 21 2356 45.6 1775 42.5
22 – 24 3191 49.2 2942 49.4
25 – 26 307 5.2 357 8.1
Age at sexual debut, years
10 – 16 3081 56.0 2623 53.6
17 – 25 2749 45.0 2420 46.4
Number of sex partners, past year
0 459 6.9 489 9.3
1 3711 65.6 2604 51.6
2 – 50 1629 27.5 1914 39.1
Sexuality
100% heterosexual 5600 96.1 5000 98.9
Not 100% heterosexual 227 3.9 58 1.1
Perceived risk of prevalent STI
Low 5398 96.7 4659 96.1
Moderate or high 211 3.3 187 3.9
Perceived risk of lifetime HIV
infection
Low 5647 97.7 4844 96.6
Moderate or high 148 2.3 182 3.4
STI symptoms, past year
Symptoms 1653 28.7 451 9.3
No Symptoms 4165 71.3 4580 90.7
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Females (n=5854) Males (n=5074)
Characteristic Number of
Participants
Weighted
Percent
Number of
Participants
Weighted
Percent
STI test, past year
Test 2172 36.9 902 18.2
No test 3631 63.1 4128 81.8
STI diagnosis, past year
Diagnosis 840 14.1 228 4.3
No diagnosis 4919 85.8 4765 95.7
Insurance status
Insurance 4612 77.1 3615 71.0
No insurance 1211 22.9 1431 29.0
Recent health care use
Within past year 5473 93.9 3650 72.5
Longer than past year 375 6.1 1406 27.5
Forgone care, past year
Forgone care 1422 23.3 1261 24.3
No forgone care 4428 76.7 3809 75.7
Antibiotic use, past 30 days
Antibiotic 943 16.8 537 11.0
No antibiotic 4904 83.2 4531 89.0
Hormonal contraception use,
current
Contraception 3724 64.8 3057 62.2
No Contraception 2101 35.2 1977 37.8
Condom use, past year
100% use 1440 23.6 1633 32.1
Not 100% use 4352 76.4 3379 67.9
Pregnancy history, females only
Ever pregnant 2477 42.0
Never pregnant 3331 58.0
Marital status
Married 1356 23.4 806 15.1
Not married 4498 76.6 4266 84.9
Housing
Shared housing 2592 42.7 2712 52.7
Live alone 3262 57.3 2360 47.3
Student status
Student 2224 37.2 1606 31.0
Not a student 3629 62.8 3465 69.0
High school graduate
Graduate 5335 90.0 4529 88.0
Not a graduate 516 10.0 542 12.0
Military history
Ever military 97 1.5 367 6.8
Never military 5752 98.5 4702 93.2
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Females (n=5854) Males (n=5074)
Characteristic Number of
Participants
Weighted
Percent
Number of
Participants
Weighted
Percent
Employment status
Job 3989 67.8 3764 74.4
No job 1865 32.2 1310 25.6
Functional poverty, past year
Able to pay rent, utilities 5502 93.8 4841 95.9
Unable to pay rent, utilities 323 6.2 205 4.1
STI, sexually transmitted infection
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Table 4.2 Bivariate Association of Prevalent Chlamydial Infection and Potential Predictor
Characteristics among Sexually Experienced Respondents by Gender, National Longitudinal
Study of Adolescent Health, 2001 – 2002
Characteristic Females Males
Prevalence Odds Ratio
(95% CI)
Prevalence Odds Ratio
(95% CI)
Race/ethnicity
White 1.0 1.0
Black 5.7 (3.9 – 8.5) 8.0 (4.9 –13.1)
Latino 1.8 (1.1 – 2.9) 5.3 (2.9 – 9.9)
Asian American 1.2 (0.5 – 2.8) 1.0 (0.3 – 2.8)
Native American 6.1 (2.3 – 16.1) 5.7 (2.1 – 15.6)
p < 0.001 p < 0.001
Partner’s race/ethnicity
White 1.0 1.0
Black 6.9 (4.5 – 10.5) 5.9 (3.4 – 10.4)
Latino 2.3 (1.0 – 5.0) 3.5 (1.6 – 7.8)
Other 1.7 (0.8 – 3.8) 1.6 (0.5 – 5.1)
p < 0.001 p < 0.001
Region
South 1.4 (0.9 – 2.1) 1.7 (1.1 – 2.8)
Outside South 1.0 1.0
p = 0.10 p = 0.03
Age, years
18 – 21 1.5 (1.1 – 2.2) 1.0 (0.6 – 1.5)
22 – 24 1.0 1.0
25 – 26 2.1 (1.3 – 3.5) 0.8 (0.4 – 1.6)
p < 0.01 p = 0.82
Age at sexual debut, years
10 – 16 1.4 (1.0 – 2.0) 2.0 (1.3 –3.0)
17 – 25 1.0 1.0
p = 0.04 p < 0.01
Number of sex partners, past year
0 1.0 1.0
1 3.4 (1.4 – 8.5) 1.6 (0.7 – 3.3)
2 – 50 7.4 (2.8 –19.2) 2.3 (1.1 – 5.0)
p < 0.001 p = 0.04
Sexuality
100% heterosexual 1.0 1.0
Not 100% heterosexual 0.6 (0.2 – 1.6) 2.6 (0.8 – 8.8)
p = 0.31 p = 0.11
Perceived risk of prevalent STI
Low 1.0 1.0
Moderate or high 5.5 (3.1 – 9.8) 5.2 (2.6 –10.4)
p < 0.001 p < 0.001
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Characteristic Females Males
Prevalence Odds Ratio
(95% CI)
Prevalence Odds Ratio
(95% CI)
Perceived risk of HIV infection
Low 1.0 1.0
Moderate or high 2.0 (0.9 – 4.5) 2.4 (1.1 – 5.1)
p = 0.09 p = 0.03
STI symptoms, past year
Symptoms 1.0 (0.7 – 1.4) 2.4 (1.5 – 3.8)
No Symptoms 1.0 1.0
p = 0.99 p < 0.001
STI test, past year
Test 1.1 (0.8 – 1.5) 1.1 (0.8 – 1.9)
No test 1.0 1.0
p = 0.53 p = 0.68
STI diagnosis, past year
Diagnosis 1.6 (1.0 – 2.4) 2.6 (1.4 – 5.0)
No diagnosis 1.0 1.0
p = 0.04 p < 0.01
Insurance status
Insurance 1.0 1.0
No insurance 1.4 (0.99 – 2.0) 1.9 (1.2 – 3.0)
p = 0.08 p = 0.01
Recent health care use
Within past year 1.0 1.0
Longer than past year 0.8 (0.4 – 1.6) 1.4 (0.99 – 2.0)
p = 0.60 p = 0.08
Forgone care, past year
Forgone care 1.2 (0.8 – 1.6) 1.2 (0.8 – 1.8)
No forgone care 1.0 1.0
p = 0.32 p = 0.34
Antibiotic use, past 30 days
Antibiotic 1.0 1.0
No antibiotic 1.5 (0.99 – 2.3) 2.9 (1.4 – 6.2)
p = 0.06 p = 0.01
Hormonal contraception use
Contraception 1.0 1.0
No Contraception 1.4 (0.9 – 2.0) 1.1 (0.8 – 1.6)
p = 0.11 p = 0.43
Condom use, past year
100% use 1.0 1.0
Not 100% use 1.0 (0.7 – 1.5) 0.9 (0.6 – 1.4)
p = 0.81 p = 0.65
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Characteristic Females Males
Prevalence Odds Ratio
(95% CI)
Prevalence Odds Ratio
(95% CI)
Pregnancy history, females only
Never pregnant 1.0
Ever pregnant 1.8 (1.2 – 2.5)
p < 0.01
Marital status
Married 1.0 1.0
Not married 2.6 (1.5 – 4.4) 1.3 (0.8 – 3.0)
p < 0.01 p = 0.30
Housing
Shared housing 1.3 (0.9 – 1.9) 2.3 (1.5 – 3.7)
Live alone 1.0 1.0
p = 0.17 p < 0.001
Student status
Student 1.0 1.0
Not a student 1.8 (1.2 – 2.6) 1.6 (1.1 – 2.6)
p < 0.01 p = 0.03
High school graduate
Graduate 1.0 1.0
Not a graduate 1.4 (0.9 – 2.1) 2.2 (1.3 – 3.6)
p = 0.17 p < 0.01
Military history
Never military 1.0 1.0
Ever military 2.9 (1.2 – 5.5) 1.6 (0.9 – 3.0)
p = 0.01 p = 0.13
Employment status
Job 1.0 1.0
No job 1.3 (0.9 – 1.8) 1.8 (1.2 – 2.8)
p = 0.14 p = 0.01
Functional poverty, past year
Able to pay rent, utilities 1.0 1.0
Unable to pay rent, utilities 1.4 (0.8 – 2.5) 1.1 (0.5 – 2.5)
p = 0.21 p = 0.81
CI, confidence interval; STI, sexually transmitted infection
p-value for adjusted Wald F-test
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Table 4.3a Adjusted Odds Ratios and Risk Scores of Prevalent Chlamydial Infection by Predictor Characteristics among Sexually
Experienced Females, National Longitudinal Study of Adolescent Health, 2001 – 2002
Characteristic Model with Respondent Race
Information (n=5239)
Model with Partner Race
Information (n=4455)
Model with No Race
Information (n=5252)
area under ROC curve=0.7654 area under ROC curve=0.7519 area under ROC curve=0.6950
OR (95% CI)  W U OR (95% CI)  W U OR (95% CI)  W U
Race/ethnicity
White 1.0 0 0
Black 5.6 (3.7–8.3) 1.72 3 1
Latino 1.5 (0.9–2.8) 0.44 1 1
Asian American 1.5 (0.6–3.7) 0.39 1 1
Native American 6.5 (2.3–18.7) 1.88 4 1
Partner race/ethnicity
White 1.0 0 0
Black 6.3 (4.1–9.8) 1.85 4 1
Latino 2.0 (0.8–5.1) 0.72 1 1
Other 1.9 (0.8–4.1) 0.62 1 1
Number of partners, past year
0 1.0 0 0 1.0 0 0 1.0 0 0
1 4.0 (1.5–10.7) 1.39 3 1 3.4 (1.1–10.9) 1.23 2 1 4.0 (1.5–10.9) 1.40 3 1
2 – 50 8.1 (3.0–21.8) 2.09 4 1 6.0 (1.9–19.2) 1.80 4 1 7.4 (2.7–20.5) 2.01 4 1
Perceived risk of prevalent STI
Low 1.0 0 0 1.0 0 0 1.0 0 0
Moderate or high 3.5 (1.8–6.5) 1.24 2 1 3.3 (1.7–6.4) 1.21 2 1 3.7 (2.1–6.3) 1.30 3 1
Student status
Student 1.0 0 0 1.0 0 0 1.0 0 0
Not a student 2.2 (1.4–3.3) 0.77 2 1 1.9 (1.2–2.9) 0.63 1 1 2.0 (1.3–3.0) 0.68 1 1
Age, years
18 – 21 1.7 (1.2–2.3) 0.52 1 1 1.5 (1.1–2.2) 0.43 1 1
22 – 24 1.0 0 0 1.0 0 0
25 – 26 1.9 (1.0–3.4) 0.62 1 1 2.1 (1.2–3.7) 0.74 1 1
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Characteristic Model with Respondent Race
Information (n=5239)
Model with Partner Race
Information (n=4455)
Model with No Race
Information (n=5252)
area under ROC curve=0.7654 area under ROC curve=0.7519 area under ROC curve=0.6950
OR (95% CI)  W U OR (95% CI)  W U OR (95% CI)  W U
Marital status
Married 1.0 0 0
Not married 2.8 (1.5–5.2) 1.03 2 1
Pregnancy history
Never pregnant 1.0 0 0
Ever pregnant 1.8 (1.2–2.6) 0.57 1 1
Hormonal contraception
Contraception 1.0 0 0
No contraception 1.5 (1.0–2.4) 0.44 1 1
Constant – 6.03 – 5.64 – 6.64
ROC, receiver operating characteristic; OR, odds ratio; CI, confidence interval; , regression coefficient; W, weighted score; U,
unweighted score; STI, sexually transmitted infection
65
Table 4.3b Adjusted Odds Ratios and Risk Scores of Prevalent Chlamydial Infection by Predictor Characteristics among Sexually
Experienced Males, National Longitudinal Study of Adolescent Health, 2001 – 2002
Characteristic Model with Respondent Race
Information (n=4529)
Model with Partner Race
Information (n=3614)
Model with No Race Information
(n=4541)
area under ROC curve=0.7447 area under ROC curve=0.7481 area under ROC curve=0.6894
OR (95% CI)  W U OR (95% CI)  W U OR (95% CI)  W U
Race/ethnicity
White 1.0 0 0
Black 7.0 (4.3–11.3) 1.94 4 1
Latino 4.1 (2.2–7.3) 1.40 3 1
Asian American 1.0 (0.4–2.9) 0.02 0 1
Native American 5.4 (2.0–14.2) 1.68 3 1
Partner race/ethnicity
White 1.0 0 0
Black 4.2 (2.3–7.8) 1.45 3 1
Latino 2.7 (1.2–6.1) 1.01 2 1
Other 1.6 (0.5–5.6) 0.49 1 1
Perceived risk of prevalent STI
Low 1.0 0 0 1.0 0 0 1.0 0 0
Moderate or high 3.5 (1.8–6.9) 1.26 3 1 3.5 (1.4–9.0) 1.27 3 1 4.1 (2.1–8.0) 1.42 3 1
Military history
Never military 1.0 0 0 1.0 0 0 1.0 0 0
Ever military 2.4 (1.2–4.9) 0.89 2 1 2.2 (0.99–5.1) 0.80 2 1 1.9 (1.0–3.7) 0.66 1 1
Region
Outside South 1.0 0 0 1.0 0 0
South 2.1 (1.3–3.5) 0.75 1 1 1.9 (1.2–3.0) 0.63 1 1
Housing
Shared housing 2.0 (1.2–3.2) 0.68 1 1 1.9 (1.1–3.3) 0.66 1 1 2.3 (1.4–3.6) 0.82 2 1
Live alone 1.0 0 0 1.0 0 0 1.0 0 0
High school graduate
Graduate 1.0 0 0 1.0 0 0 1.0 0 0
Not a graduate 1.7 (1.0–3.1) 0.56 1 1 2.2 (1.1–4.5) 0.80 2 1 1.8 (1.0–3.3) 0.60 1 1
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Characteristic Model with Respondent Race
Information (n=4529)
Model with Partner Race
Information (n=3614)
Model with No Race Information
(n=4541)
area under ROC curve=0.7447 area under ROC curve=0.7481 area under ROC curve=0.6894
OR (95% CI)  W U OR (95% CI)  W U OR (95% CI)  W U
Recent health care use
Within past year 1.0 0 0
Longer than past year 1.5 (1.0–2.1) 0.39 1 1
Antibiotic use, past 30 days
Antibiotic 1.0 0 0
No antibiotic 2.9 (1.3–6.7) 1.07 2 1
STI diagnosis, past year
Diagnosis 1.0 0 0
No diagnosis 1.9 (1.2–3.2) 0.66 1 1
Age at sexual debut, years
10 – 16 1.0 0 0
17 – 25 1.7 (1.1–2.9) 0.56 1 1
Number of partners, past year
0 1.0 0 0
1 1.4 (0.6–3.0) 0.33 1 1
2 – 50 1.5 (0.6–3.3) 0.39 1 1
Constant – 4.87 – 4.97 – 6.03
ROC, receiver operating characteristic; OR, odds ratio; CI, confidence interval; , regression coefficient; W, weighted score; U,
unweighted score; STI, sexually transmitted infection
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Table 4.4a Performance of Selective Screening Criteria among Sexually Experienced Females, National Longitudinal Study of
Adolescent Health, 2001 – 2002
Percent Model with Respondent Race
Information (n=5239)
Model with Partner Race
Information (n=4455)
Model with No Race
Information (n=5252)
Tested Cutoff Sensitivity Specificity Cutoff Sensitivity Specificity Cutoff Sensitivity Specificity
Predicted Probability
< 70 0.02 87.6 45.0 0.02 82.0 58.7 0.02 90.9 31.7
< 50 0.03 81.7 56.5 0.02 82.0 58.7 0.04 76.6 52.4
< 30 0.05 69.9 73.8 0.04 64.6 74.0 0.05 62.1 71.9
Weighted Risk Score
< 70 6 84.1 53.3 4 81.3 53.5 7 80.4 48.0
< 50 6 84.1 53.3 4 81.3 53.5 8 60.1 73.0
< 30 7 66.9 76.4 6 61.0 80.1 8 60.1 73.0
Unweighted Risk Score
< 70 3 74.7 59.4 3 54.3 77.8 4 77.5 48.9
< 50 3 74.7 59.4 3 54.3 77.8 5 46.7 79.9
< 30 4 31.9 91.3 3 54.3 77.8 5 46.7 79.9
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Table 4.4b Performance of Selective Screening Criteria among Sexually Experienced Males, National Longitudinal Study of
Adolescent Health, 2001 – 2002
Percent Model with Respondent Race
Information (n=4529)
Model with Partner Race
Information (n=3614)
Model with No Race
Information (n=4541)
Tested Cutoff Sensitivity Specificity Cutoff Sensitivity Specificity Cutoff Sensitivity Specificity
Predicted Probability
< 70 0.01 94.3 31.3 0.01 87.3 37.2 0.02 90.6 32.7
< 50 0.02 83.3 53.9 0.02 82.5 52.9 0.03 78.1 52.1
< 30 0.04 72.2 73.3 0.03 72.2 73.8 0.04 59.0 74.0
Weighted Risk Score
< 70 2 82.5 55.3 2 84.7 49.7 5 87.3 39.8
< 50 2 82.5 55.3 3 74.5 68.0 6 67.7 64.0
< 30 4 70.2 74.9 4 63.0 81.0 7 46.8 84.2
Unweighted Risk Score
< 70 2 71.7 61.7 2 80.3 57.6 4 79.2 51.4
< 50 2 71.7 61.7 2 80.3 57.6 4 79.2 51.4
< 30 3 42.8 89.1 3 46.6 86.2 5 50.4 81.6
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Table 4.5a Performance of Selective Screening Criteria to Test <50% of Sexually Experienced Females by Respondent’s Race,
National Longitudinal Study of Adolescent Health, 2001 – 2002
Model with Respondent Race
Information (n=5239)
Model with Partner Race
Information (n=4455)
Model with No Race
Information (n=5252)
White Black Other White Black Other White Black Other
SEN SPE SEN SPE SEN SPE SEN SPE SEN SPE SEN SPE SEN SPE SEN SPE SEN SPE
Predicted Probability
61.9 66.9 99.4 4.9 77.1 55.2 60.2 73.9 99.4 6.4 90.8 29.0 72.5 56.1 79.0 39.9 80.5 46.5
Weighted Risk Score
61.9 67.2 99.4 4.9 94.7 31.4 64.5 66.1 94.7 3.7 88.9 34.9 55.6 75.5 61.8 63.4 68.1 70.2
Unweighted Risk Score
47.3 75.3 90.4 21.0 98.3 17.4 31.9 90.0 70.3 41.5 70.5 49.2 42.0 82.7 48.5 74.1 54.6 72.3
SEN, sensitivity; SPE, specificity
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Table 4.5b Performance of Selective Screening Criteria to Test <50% of Sexually Experienced Males by Respondent’s Race, National
Longitudinal Study of Adolescent Health, 2001 – 2002
Model with Respondent Race
Information (n=4529)
Model with Partner Race
Information (n=3614)
Model with No Race
Information (n=4541)
White Black Other White Black Other White Black Other
SEN SPE SEN SPE SEN SPE SEN SPE SEN SPE SEN SPE SEN SPE SEN SPE SEN SPE
Predicted Probability
42.0 74.5 100 0 99.7 6.9 56.1 66.5 99.4 6.7 87.0 28.1 65.6 57.3 83.9 28.9 81.8 47.9
Weighted Risk Score
42.0 74.5 100 0 96.8 16.2 33.7 81.1 96.8 13.4 86.6 52.1 58.7 69.2 71.4 45.2 71.1 56.3
Unweighted Risk Score
31.2 78.1 86.2 25.5 90.9 18.6 56.1 68.9 94.1 20.6 86.8 35.8 65.6 56.4 83.4 28.4 86.6 48.0
SEN, sensitivity; SPE, specificity
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Table 4.6a Performance of Selective Screening Criteria to Test <50% of Population of Sexually Experienced Females by
Respondent’s Race, National Longitudinal Study of Adolescent Health, 2001 – 2002
Model with Respondent
Race Information
Model with Partner
Race Information
Model with No
Race Information
White Black Other White Black Other White Black Other
Subpopulation 4,644,760 945,760 935,181 4,644,760 945,760 935,181 4,644,760 945,760 935,181
Number of
infections
(130,771) (142,776) (40,995) (130,771) (142,776) (40,995) (130,771) (142,776) (40,995)
Predicted Probability
Infections
detected
80,476 142,350 30,467 78,744 141,957 37,209 94,241 110,927 32,207
Tests among
uninfected
1,497,806 763,240 395,175 1,178,214 751,707 634,648 20,22,722 499,754 491,501
Weighted Risk Score
Infections
detected
80,476 142,350 38,249 84,299 135,240 36,463 71,189 90,716 27,114
Tests among
uninfected
1,490,527 763,240 611,534 1,532,016 773,572 582,162 1,141,263 318,130 276,393
Unweighted Risk Score
Infections
detected
59,157 127,225 40,098 41,667 100,435 28,909 58,780 75,345 23,496
Tests among
uninfected
1,105,094 634,370 742,951 449,814 469,847 454,571 824,402 226,904 264,591
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Table 4.6b Performance of Selective Screening Criteria to Test <50% of Population of Sexually Experienced Males by Respondent’s
Race, National Longitudinal Study of Adolescent Health, 2001 – 2002
Model with Respondent
Race Information
Model with Partner
Race Information
Model with No
Race Information
White Black Other White Black Other White Black Other
Subpopulation 4,276,592 838,491 958,632 4,276,592 838,491 958,632 4,276,592 838,491 958,632
Number of
infections
(60,848) (80,756) (55,640) (60,848) (80,756) (55,640) (60,848) (80,756) (55,640)
Predicted Probability
Infections
detected
24,964 80,756 55,508 34,142 80,287 48,383 40,114 66,179 45,025
Tests among
uninfected
1,032,140 757,735 839,715 1,412,997 705,771 649,052 1,761,285 526,613 449,725
Weighted Risk Score
Infections
detected
24,964 80,756 55,508 20,529 78,202 48,186 36,750 54,152 39,023
Tests among
uninfected
1,032,140 757,735 744,493 795,655 656,299 432,242 1,255,578 403,546 368,593
Unweighted Risk Score
Infections
detected
16,367 69,822 48,700 34,142 75,961 48,309 40,114 65,287 48,714
Tests among
uninfected
879,713 552,387 724,975 1,310,123 601,589 579,504 1,797,801 538,094 450,062
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Figure 4.1a Sensitivity of Predicted Probabilities by Percentage of Population Tested among
Sexually Experienced Females, National Longitudinal Study of Adolescent Health, 2001 –
2002
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Figure 4.1b Sensitivity of Predicted Probabilities by Percentage of Population Tested among
Sexually Experienced Males, National Longitudinal Study of Adolescent Health, 2001 –
2002
0
10
20
30
40
50
60
70
80
90
100
0 10 20 30 40 50 60 70 80 90 100
Percentage of Population Tested
Se
n
si
tiv
ity
race model
partner race model
no race model
CHAPTER 5
RESULTS AIM TWO: PARTNER AGE DIFFERENCE AND CHLAMYDIAL
INFECTION AMONG YOUNG ADULT WOMEN
Among adolescents and young adults, Chlamydia trachomatis is the most common
bacterial sexually transmitted infection (STI) in the United States (US) (1). An estimated
three million new infections occur each year. Chlamydial infection may cause pelvic
inflammatory disease, ectopic pregnancy, and tubal infertility in women (4-6). Infection also
increases susceptibility to and transmission of HIV in women and men (9, 156). Despite
prevention and treatment measures, chlamydial infection continues to cause substantial
morbidity.
Sexual mixing between members of different groups facilitates the spread of STI (18-
21). Partner mixing by age is common among both adolescents and adults (22, 23).
Adolescent girls with older male partners are more likely than girls with partners close in age
to practice behaviors such as young age at first sex and inconsistent condom use, which are
risk factors for STI (24-31). Whether this relation between older partners and risky behavior
continues beyond adolescence is unclear. Two studies reporting the effect of partner age
difference on STI among adults found little association with older partners, but both studies
had major limitations. One study diagnosed chlamydial infection by culture (18), a
diagnostic method that is no longer the gold standard (157). The other study relied on self-
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report of STI test or treatment in the past year (23), which is again a sub-optimal method of
determining infection status. These findings suggest that older male partners may play a
lesser role in risk of STI as adolescent girls mature into adulthood.
The mechanism by which age difference affects risk of STI may be twofold. First,
age discordant partnerships are purported to represent relationships with unequal distribution
of power (30, 158). A younger woman may have more difficulty confronting sexual
pressures, negotiating condom use or influencing her partner’s sexual behavior with an older
man rather than someone her own age. Second, partnerships between members of different
sexual networks or populations have been linked to higher rates of chlamydial infection (18,
114). Age discordant partnerships among adolescents may facilitate mixing between
populations with low and high STI prevalence (18, 39, 115, 124). Age-stratified rates of
reported chlamydial infection differ across gender, with the highest reported rates among
females aged 15 – 19 and males aged 20 – 24 (2).
Wave III of the National Longitudinal Study of Adolescent Health (Add Health)
provides the necessary demographic, personal history, and behavior data together with
laboratory-diagnosed STI results to examine the association between partner age difference
and prevalent chlamydial infection among young adult women.
METHODS
Study Design and Sample
Add Health is a three-wave prospective cohort study that followed nearly 20,000
adolescents into adulthood from September 1994 to May 2002 (146). For this study, we
conducted a cross-sectional analysis of Wave III (April 2, 2001 to May 9, 2002), which
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targeted all Wave I participants. Our study population was restricted to female Wave III
participants who answered “Yes” when asked “Have you ever had vaginal intercourse?” The
University of North Carolina institutional review board approved all study procedures.
Add Health’s two-stage sampling has been described in detail elsewhere (146, 147).
In short, a systematic random sample of secondary schools was chosen with unequal
probability of selection. The sample was stratified so that selected schools were
representative of all US secondary schools with respect to region, urbanicity, and percent
black and white. The original study participants were drawn from students in grades seven
through 12 enrolled in the selected schools. Certain populations, including black students
with a college-educated parent, Cubans, and Puerto Ricans, were oversampled to increase
estimate precision for these groups. Post-stratification sampling weights account for persons
who refused to participate or could not be located. The Add Health Wave III cohort, when
incorporating design effect, provides a representative sample of young adults aged 18 to 26
years residing in the US.
Interview and Specimen Collection
Wave III sought participation from all original Wave I respondents who could be
contacted. The in-home interviewer recorded responses into a laptop computer for non-
sensitive issues. The participant used computer-assisted self-interview to enter responses
directly into the computer for sensitive issues such as sexual experiences and behaviors.
Respondents who consented to provide a urine specimen for Chlamydia trachomatis
testing received $10. A more detailed report of Add Health STI testing is available
elsewhere (132). Cooled urine specimens were shipped by overnight express to the
University of North Carolina at Chapel Hill for diagnostic testing.
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Urine specimens were tested for C. trachomatis per manufacturer instructions using
ligase chain reaction (LCR™) amplification technology in the Abbott LCx® Probe System
(Abbott Laboratories, Abbott Park, IL). Specimens were tested even if they exceeded the
recommended volume.
Measures
The outcome variable was a positive test result for C. trachomatis. The primary
exposure was the difference in years between each female study participant and her most
recent male sex partner. A negative age difference meant the woman’s partner was younger;
a positive age difference meant the woman’s partner was older. Additionally, as a secondary
exposure, we used the age difference of the most age discordant partner in the past year. The
exposure measures were categorized to reflect substantively meaningful age differences.
Potential modifying or confounding covariates were derived from the set of self-reported
demographic, behavior, and health care factors available from the in-home interview.
Statistical Analyses
Analysis was performed using Stata Version 7.0 (Stata Corporation, College Station,
TX). Analyses accounted for Add Health’s complex survey design by using school as the
primary sampling unit, region of the country as the stratification variable, and post-
stratification weights. In preliminary analyses, we examined the frequency distribution of the
outcome, primary and secondary exposures, and other covariates. We calculated bivariate
prevalence odds ratios (OR) and 95 percent confidence intervals (CI) to assess the relation
between the covariates and chlamydial infection.
Mixing by age within a partnership can be assortative (like-with-like), disassortative
(like-with-unlike), or random. The Q statistic, defined as ( iwi – 1)/(N – 1), where wi is the
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matrix eigen value, uses an N*N mixing matrix to identify high or low within-group mixing
(18, 141). For our analyses, the matrix rows were the categorized age of the woman and the
matrix columns were the categorized age of the male partner, calculated for the two partner
age difference measures. This assessment could not incorporate survey weighting.
We used unconditional multiple logistic regression for survey data with a backwards
elimination strategy (142). Covariates that could alter the association between age difference
and prevalent chlamydial infection were included in the full model. We tested the null
hypothesis that interaction terms between the exposure and each potential modifier were
equal to zero, and looked for substantive changes between unstratified and stratified effect
estimates. After examination and removal of interaction terms, we eliminated potentially
confounding covariates one at a time from the model beginning with the variable with the
largest p-value. We evaluated confounding by comparing the crude, adjusted, and fully
adjusted effect estimates. We retained the covariate if the change in estimates was greater
than 10 percent (143). Otherwise, the covariate was dropped. Backwards elimination
stopped when all covariates that neither modified nor confounded the association between
age difference and chlamydial infection were removed from the model. We examined the
final model for collinearity and overly influential covariate patterns. Primary and secondary
exposure measures were evaluated through separate but identical processes.
RESULTS
Study Population
Of the 18,924 Add Health participants in the nationally representative Wave I sample,
1,109 (5.9%) refused participation, 3,493 (18.5%) could not be located or were unable to
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participate, and 14,322 (75.7%) were located and agreed to participate in Wave III. Of these,
6,594 were females who reported ever having vaginal intercourse (87.2% of all Wave III
females). C. trachomatis test results were available for 5,854 (88.8%) of the sexually
experienced females. Reasons for unavailable test results included inability or refusal to
provide a urine specimen, processing errors due to shipping, or laboratory problems.
The overall prevalence of chlamydial infection among sexually experienced women
was 5.1 percent (95% CI: 4.2%–6.0%; table 1). The majority of women with test results was
white (68.2%), with representation of black (17.1%), Latino (11.0%), Asian American
(2.9%), and Native American (0.8%) women. The mean age was 21.8 years (standard error
(SE), 0.1 years), the mean age at first sex was 16.3 years (SE, 0.1 years) and the mean
number of sex partners in the past year was 1.5 partners (SE, 0.04 partners). The mean age
difference of the most recent partner was 2.9 years (SE, 0.1 years, figure 1) and mean age
difference of the most age discordant partner in the past year was 3.4 years (SE, 0.1 years,
figure 2).
Bivariate Analyses
There was little difference in chlamydial prevalence between women with a most
recent partner two to eight years younger (“youngest”; OR 1.9, 95% CI: 1.0 – 3.7) and
women with a most recent partner six or more years older (“oldest”; OR 1.6, 95% CI: 0.9 –
2.9) as compared to women with a most recent partner one year older or younger (the
referent, “close in age”; table 2). The similarity of the effect estimates across age difference
categories persisted when examining the secondary exposure measure, age difference of the
most age discordant partner (youngest OR 2.4, 95% CI: 1.2 – 4.7; oldest OR 2.1, 95% CI: 1.2
– 3.4).
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The Q statistics for the age difference with the most recent partner (Q=0.3) and the
most age discordant partner (Q=0.2) indicated that mixing by age between women and their
partners was random, with a tendency towards assortative (like-with-like) mixing.
Multivariate Analyses
Overall. In multiple logistic regression analyses, the odds of prevalent chlamydial
infection among women with the youngest partners were approximately two times greater
(most recent OR 1.8, 95% CI: 0.9 – 3.5; most discordant OR 2.1, 95% CI: 1.1 – 4.3) than
among women with partners close in age, adjusting for number of partners in the past year
(table 3). Among women with older partners, the adjusted odds of infection differ little
between partners two to five years older (most recent OR 1.4, 95% CI: 0.9 – 2.3; most
discordant OR 1.4, 95% CI: 0.8 – 2.3) and partners six or more years older (most recent OR
1.6, 95% CI: 0.9 – 2.8; most discordant OR 1.7, 95% CI: 1.0 – 2.8) as compared to partners
within one year’s age. The relation between partner age difference and chlamydial infection
is consistent for the two exposure measures, although the estimates are imprecise. These
associations did not vary by women’s age or number of sex partners in the past year.
Stratified by Race. The relation between most discordant partner age difference and
chlamydial infection did vary by women’s race/ethnicity (interaction p=0.1). For white
women, the greatest odds of infection are among those with the oldest partners (OR 2.8, 95%
CI: 1.2 – 6.9) compared to partners close in age, adjusting for age, highest attained education,
and number of partners in the past year (table 3). Youngest partners have little effect on
adjusted odds of infection for this group (OR 1.2, 95% CI: 0.2 – 6.4). The associations are
reversed, however, among black women. For black women, the adjusted odds ratio is
greatest for the youngest partners (OR 3.2, 95% CI: 1.2 – 9.0) and shows little effect for the
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oldest partners (OR 0.7, 95% CI: 0.3 – 1.4) as compared to partners close in age. The
unstratified effect estimate showing the largest odds ratio for the youngest partners is clearly
moderated by the experience of black women, who comprise only 17 percent of the study
population.
Qualitatively similar results were seen for the stratified association between most
recent partner age difference and chlamydial infection, although the variation across
race/ethnicity was not statistically significant (interaction p=0.3; table 3). Only among
Latino women is there a substantial difference between the two stratified exposure measures,
with consistently stronger estimated effects for the most discordant, rather than most recent,
partner age difference.
DISCUSSION
Among young adult women, older partners are moderately associated with prevalent
chlamydial infection. A similar association was observed for younger partners as compared
to partners within one year’s age. These associations remain consistent when examining the
age difference with the most recent partner and the most age discordant partner in the past
year. This finding in young adults contrasts with previous studies of adolescent girls, for
whom those with older partners were four times more likely to be infected with chlamydia
(24).
The relation between most age discordant partner and chlamydial infection varies by
women’s race/ethnicity. The divergent effect on STI of older partners for white women and
younger partners for black women may result from racial/ethnic differences in age-dependent
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sexual behaviors or rates of chlamydial infection (2, 159). These results, however, should be
interpreted cautiously because of the imprecision inherent in stratification.
It is unclear how the diminished overall association between partner age and
chlamydial infection develops from adolescence to young adulthood, but several
explanations are possible. Physical and emotional maturity may prepare a young woman to
better protect herself by exercising more power in sexual decision-making. Older partners
for young adults may also represent a different population than older partners for adolescents,
both in terms of age-specific prevalence and social networks. Adolescents likely need to
reach beyond their social setting to meet older partners. These partners may be links to
networks with higher risk behaviors like multiple and overlapping partners, drug use, and
transactional sex. Age is merely a marker for these risky behaviors. Alternatively, young
adults may have more opportunities to meet older partners in their usual social network.
Although the partners are older, they may be similar with respect to risk behaviors.
Few studies have rigorously assessed the association between partner age difference
and prevalent chlamydial infection in young adult, rather than adolescent, females. Our
study offers improvement over these earlier works by using nucleic acid amplification
detection of chlamydial infection rather than culture (18) or self-report of recent or lifetime
STI test, treatment, or diagnosis (23). Nucleic acid amplification testing is approximately 90
percent sensitive and 99 percent specific (69). Chlamydial culture is a considerably less
sensitive diagnostic tool and is no longer the optimal diagnostic method (157). Results
reliant on self-report of STI test are also subject to numerous biases. Moreover, evaluating
chlamydial infection alone recognizes the distinct epidemiology and age distribution across
the spectrum of STI.
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Using the age difference with both the most recent and the most age discordant
partner in the past year mitigates a limitation common to earlier investigations of partner age
difference and STI. Since untreated chlamydial infection can persist for an extended period
of time (160), the most recent partner may not be the source of a prevalent infection. Our
findings show comparable estimated effects when examining either measure. Additionally,
we assessed the applicability of calculating the exposure measure as the absolute difference
in ages rather than subtracting the woman’s age from that of her partner. The dose-response
remained non-linear for the absolute difference, with the maximum observed effect at a
difference of six to 10 years (p= 0.05).
Implicit in a difference between the age of the most recent partner and the age of the
most age discordant partner is the existence of multiple partners. While we controlled for the
number of partners, other unmeasured confounding behaviors that can only occur in the
presence of multiple partners, like concurrency or shortened time between partners, might be
important. Furthermore, type of partner may be of differential importance across the two
exposure measures. Women with more than one partner in the past year may be more likely
to have a main and a casual partner whereas women with a single partner may be more likely
to have only a main partner. Type of partner may play a primary role in transmission of
infection (161-163).
Our study findings are limited by the quality of both the study sample and the
diagnostic test. The quality of our study sample depends on how well the original school-
based sample represented all students attending US secondary schools, response to the Wave
III follow-up survey, valid reporting of sexual experiences, and reason for missing diagnostic
outcome. The original sample included only students on school registers, but bias in Add
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Health caused by school dropouts is thought to be small (153). While 24 percent of Wave I
participants could not be located for Wave III, the post-stratification sample weight
adjustment ensured that this missing data bias is also small (154). Computer-assisted self-
interview likely improved both the frequency and validity of answers to sensitive questions
about sexual experiences (127-131). Additionally, respondents who participated in STI
testing were similar to those who did not participate (164). Prevalence estimates also are
robust to differences between survey responders and non-responders and to the performance
of the diagnostic test for chlamydial infection (3). Unavailable information like accurate
measures of partner concurrency or standard definitions of partner type would have enriched
these analyses.
Understanding the role of partners in the social dynamics of chlamydial infection is
central to developing successful public health interventions and treatment programs. Among
young adults, older and younger partners convey essentially the same elevated risk of STI as
compared to partners close in age. While other aspects of partnerships may be important, it
is doubtful that partner age difference is a major cause behind the high rates of chlamydial
infection common to young women. This finding is in clear juxtaposition to adolescent girls,
for whom older partners are a strong risk factor for STI (24, 27) and likely facilitate
maintenance of high infection rates in this group (165). This discrepancy in risk factor
between adolescents and young adults may be exploited to better understand how adolescents
in age discordant partnerships may be helped to protect themselves from STI. Programs to
assist with self-esteem, relationship communication, condom negotiation, and partner
notification may benefit by understanding why age difference is so important in STI risk
among adolescents, but not when these women are just a few years older.
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Young adults, unlike adolescents, are studied infrequently even though they continue
to remain at high risk of chlamydial infection. This investigation and other recent work
suggest that risk factors like partner age difference and age at first sex (32), which contribute
to the spread of STI among adolescents, play distinctly lesser roles in the epidemiology of
infection among young adults. Additional research focused on young adults is needed to
understand the high STI rates in this age group and to identify how these rates may be
reduced.
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Table 5.1 Characteristics of Sexually Experienced Females with Chlamydia trachomatis
Test Results (n=5854), National Longitudinal Study of Adolescent Health, 2001 – 2002
Characteristic Number of
Participants
Weighted
Percent
Chlamydial infection
Positive 316 5.1
Negative 5538 94.9
Partner age difference, most recent
–8 to –2 years 254 5.1
–1 to 1 years 1964 39.1
2 to 5 years 1839 38.6
6 to 36 years 839 17.2
Partner age difference, most discordant, past year
–8 to –2 years 254 5.8
–1 to 1 years 1484 33.1
2 to 5 years 1691 39.9
6 to 36 years 921 21.2
Age, years
18 – 21 2356 45.6
22 – 23 2248 33.2
24 – 26 1250 21.2
Race/ethnicity
White 3178 68.2
Black 1364 17.1
Latino 909 11.0
Asian American 337 2.9
Native American 53 0.8
Marital status
Married 1356 23.5
Not married 4498 76.5
Employment status
Job 3989 67.8
No job 1865 32.2
Functional poverty, past year
Able to pay rent, utilities 5502 93.8
Unable to pay rent, utilities 323 6.2
Highest attained education
High school 2621 46.3
College 3117 51.7
Graduate school 115 2.0
Antibiotic use, past 30 days
Antibiotic 943 16.8
No antibiotic 4904 83.2
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Characteristic Number of
Participants
Weighted
Percent
Age at first sex, years
10 – 15 1970 36.0
16 – 18 2975 50.3
19 – 25 885 13.7
Number of sex partners, past year
0 – 1 4170 72.6
2 – 50 1629 27.4
Condom use, past year
Never 1754 31.4
Sometimes 2598 45.0
Always/no sex 1440 23.6
Exchange sex for money/drugs, past year
Exchange 75 1.3
No exchange/no sex 5779 98.7
Regret sex, past year
Regret 747 13.4
No regret/no sex 5086 86.6
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Table 5.2 Bivariate Association between Partner Age Difference and Prevalent Chlamydial
Infection among Sexually Experienced Females, National Longitudinal Study of Adolescent
Health, 2001 – 2002
Characteristic Number of
participants
Odds ratio (95% CI)
Partner age difference, most recent
–8 to –2 years 254 1.9 (1.0 – 3.7)
–1 to 1 years 1964 1.0
2 to 5 years 1839 1.4 (0.9 – 2.1)
6 to 36 years 839 1.6 (0.9 – 2.9)
Partner age difference, most discordant, past year
–8 to –2 years 254 2.4 (1.2 – 4.7)
–1 to 1 years 1484 1.0
2 to 5 years 1691 1.4 (0.9 – 2.3)
6 to 36 years 921 2.1 (1.2 – 3.4)
CI, confidence interval
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Table 5.3 Unstratified and Stratified Adjusted Odds Ratios with 95% Confidence Intervals
for the Estimated Effect of Partner Age Difference on Prevalent Chlamydial Infection among
Sexually Experienced Females, National Longitudinal Study of Adolescent Health, 2001 –
2002
Exposure Measure
Most Recent Partner Most Age Discordant Partner,
Past Year
Age Difference Adjusted Odds Ratio (95% CI) Adjusted Odds Ratio (95% CI)
Unstratified1
–8 to –2 years 1.8 (0.9 – 3.5) 2.1 (1.1 – 4.3)
–1 to 1 years 1.0 1.0
2 to 5 years 1.4 (0.9 – 2.3) 1.4 (0.8 – 2.3)
6 to 36 years 1.6 (0.9 – 2.8) 1.7 (1.0 – 2.8)
Stratified by Race2
White
–8 to –2 years 1.0 (0.2 – 5.4) 1.2 (0.2 – 6.4)
–1 to 1 years 1.0 1.0
2 to 5 years 1.4 (0.7 – 3.8) 1.6 (0.6 – 4.3)
6 to 36 years 2.8 (1.0 – 7.3) 2.8 (1.2 – 6.9)
Black
–8 to –2 years 2.8 (0.99 – 7.7) 3.2 (1.2 – 9.0)
–1 to 1 years 1.0 1.0
2 to 5 years 1.6 (0.7 – 2.4) 1.2 (0.7 – 2.2)
6 to 36 years 0.7 (0.3 – 1.3) 0.7 (0.3 – 1.4)
Latino
–8 to –2 years 2.0 (0.3 – 13.7) 4.8 (0.7 – 35.6)
–1 to 1 years 1.0 1.0
2 to 5 years 1.9 (0.5 – 6.4) 2.9 (0.6 – 13.9)
6 to 36 years 2.4 (0.6 – 9.4) 4.5 (0.99 – 21.0)
Other
–8 to –2 years 2.2 (0.2 – 25.9) 2.0 (0.2 – 25.4)
–1 to 1 years 1.0 1.0
2 to 5 years 1.0 (0.2 – 4.5) 0.6 (0.1 – 4.2)
6 to 36 years 0.7 (0.1 – 7.8) 1.0 (0.1 – 7.5)
CI, confidence interval
1 adjusted for number of sex partners, past year
2 adjusted for age, highest attained education, and number of sex partners, past year
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Figure 5.1 Prevalence of chlamydial infection among sexually experienced females by age
difference with the most recent partner, National Longitudinal Study of Adolescent Health,
2001 – 2002. The upper range of the age difference is grouped for women with partners 26
or more years older. The symbol size is proportional to the unweighted frequency in the
data.
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Figure 5.2 Prevalence of chlamydial infection among sexually experienced females by age
difference with the most age discordant partner in the past year, National Longitudinal Study
of Adolescent Health, 2001 – 2002. The upper range of the age difference is grouped for
women with partners 26 or more years older. The symbol size is proportional to the
unweighted frequency in the data.
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CHAPTER 6
CONCLUSIONS
Chlamydial infection is the most common bacterial STI in the United States (2).
Young adults are at high risk of infection. The racial/ethnic disparity in the prevalence of
infection, even among youth, is extreme. Infection with chlamydia can lead to serious
sequelae, particularly for women (4-6, 8, 9). The economic cost of infection is also great (36,
37). Screening for chlamydial infection is a cost-effective way to prevent additional
infection and its harmful reproductive health outcomes (63, 64). Testing and treatment for
infection can lower the prevalence of infection (56, 57) and the incidence of pelvic
inflammatory disease (58).
The sexual mode of transmission makes controlling the spread of any STI difficult.
Chlamydial infection is exceptionally difficult to address because infection is most often
asymptomatic (10). Neither those individuals at risk nor health care providers can rely solely
on medical signs and symptoms for knowing when infection occurs. For this reason,
asymptomatic screening is essential to any chlamydial control program.
Current guidelines recommend annual universal testing of all sexually active women
aged 25 years or younger (14). Even with this and similar recommendations by all major US
health policy groups, screening rates remain abysmally low (11-13). Young adults are
unaware of asymptomatic STI and the importance of screening (53). Many youth do not
regularly access health care so they have limited opportunities to be tested (148-150). Many
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health care providers do not follow screening guidelines (11, 62, 66). Guidelines provide
limited information on screening men.
To expand screening coverage, testing programs must reach beyond traditional clinic
settings. Community-based testing is an acceptable alternative (166). Because community
programs may lack sufficient funds to test everyone, selective screening guidelines specific
to the general population and appropriate for community-based testing may help make such
programs feasible. Developing a rational approach for screening men is also important.
The Add Health project provided the information necessary to develop community-
based selective screening guidelines for women and men. The detailed demographic,
personal history, and behavior data, paired with laboratory-diagnosed chlamydial infection,
led to the creation of potentially useful screening tools. Applying these criteria to select no
more than 50 percent of the population for diagnostic testing could identify approximately 80
percent of infections in women and men. Implementation of these criteria, however, may be
problematic because of the inclusion of race-related information. Additionally, these
guidelines result in many unnecessary tests among persons without infection, but fewer
people would be tested unnecessarily than with universal testing.
We created three sets of criteria separately for women and men, each beginning with
identical potential predictor characteristics. We also included 1) the respondent’s
race/ethnicity; or 2) the respondent’s most recent partner’s race/ethnicity; or 3) no
information on race/ethnicity. Ideally screening guidelines would identify individuals for
testing based exclusively on behavior. In reality, the racial/ethnic disparity is so great that
either the participant’s or the partner’s race/ethnicity often is the strongest marker for STI
risk. Chlamydial infection is increased among white young adults with traditional risk
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behaviors, but black young adults are at high risk of chlamydial infection even when
practicing behaviors that are low risk for white youth (152). Given the potential problems
and controversy of selective screening guidelines that incorporate race information, we
attempted to find suitable alternative predictor characteristics. However, no other variable or
combination of variables that could serve as a proxy for socioeconomic status or other
connection to elevated prevalence remained in any of the final models. Information on
concurrent relationships or partner type was of poor quality. Detailed data on sexual
networks or environmental characteristics that may address the disparity in infection
prevalence were unavailable in these data and would not typically be used in routine
screening settings.
The presentation of these guidelines, which do include race-related information, is
neither an endorsement of their value nor an encouragement for their general use. Rather, the
purpose of presenting the selective screening criteria that include race-related information, in
conjunction with the more inefficient criteria without race information, is to illustrate that
implementation of either plan has significant and potentially harmful consequences. Perhaps
the principal lesson learned from this exercise is that at present, on a national level universal
screening is the best way to detect chlamydial infection. On a local level, programs may be
able to develop suitable screening criteria without race information that include alternative
data on geographical location or other markers of STI risk.
Institutional changes are also needed to improve screening practices among health
care providers. Health communication programs must do a better job of assisting the public
to understand the concepts of asymptomatic infection and screening. Policy changes are
needed to address health disparities on a broader scale, of which STI is only one. Ensuring
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truly universal screening for chlamydial infection would avoid the stigma of guidelines
incorporating race/ethnicity, but must be considered in a framework that assures equal access
to testing, treatment, and counseling.
In addition to the racial and ethnic disparity in the prevalence of chlamydial infection,
there is also a disparate burden of infection by gender (2). Biologic and physiologic
differences between women and men are a primary explanation for female’s higher rates of
infection (5). Social factors, though, also play an important – and modifiable – role.
Conventional wisdom holds that it is “dangerous” for young girls to have older boyfriends.
This belief is true in many respects among adolescents, for whom older partners are linked to
young age at first sex and inconsistent condom use, both risk factors for STI (24-31). An
unequal distribution of power and mixing between sexual networks with different
background rates of STI contribute to this phenomenon (18, 30, 114, 158). It was unclear
whether this relation between older partners and risky behavior continued beyond
adolescence. Two methodologically limited studies reporting the effect of partner age
difference on STI among adults found little association with older partners (18, 23).
Among young adult women in Wave III of Add Health, older partners are moderately
associated with prevalent chlamydial infection. A similar association was observed for
younger partners as compared to partners within one year’s age. These associations remain
consistent when examining the age difference with the most recent partner and the most age
discordant partner in the past year. This finding in young adults contrasts with previous
studies of adolescent girls, for whom those with older partners were four times more likely to
be infected with chlamydia (24).
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Our study mitigated several of the limitations common to earlier investigations of
partner age difference and STI. We used the most sensitive diagnostic test available,
examined partner age difference multiple ways, and assessed the importance of factors that
could modify the exposure-outcome relationship, such as race/ethnicity, age, and number of
partners. Unfortunately, good quality data on concurrent partnerships were unavailable.
The cross-sectional design was an additional drawback. We examined prevalent infection so
could not determine if the exposure partner was the partner transmitting infection.
Understanding the role of partners in the social dynamics of chlamydial infection is
central to developing successful public health interventions and treatment programs. The
incongruent risk of older partners for adolescents and young adults can inform future STI
research. Programs to assist with self-esteem, relationship communication, condom
negotiation, and partner notification may benefit from a better understanding of why age
difference is so important in STI risk among adolescents, but not among young adults.
Whatever changes occur during the intervening years reduces the impact of partner age
difference from a major to a minor risk factor. Identifying these changes, and then
incorporating them into prevention and counseling programs, may help adolescent girls
sidestep a significant STI risk a few years earlier than would have occurred otherwise.
Young adults, unlike adolescents, are studied infrequently even though they continue
to remain at high risk of chlamydial infection. This investigation and other recent work
suggests that risk factors like partner age difference and age at first sex (32), which
contribute to the spread of STI among adolescents, play distinctly lesser roles in the
epidemiology of infection among young adults. Additional research focused on young adults
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is needed to understand the high STI rates in this age group and to identify how these rates
may be reduced.
Add Health is an excellent data source for the study of STI in young adults. The data
are the most comprehensive assessment to date of chlamydial infection and related risk
factors in US young adults. Few population-based studies provide such detailed information
on this age group. Our study findings, though, are limited by the adequacy of the Add Health
study sample and the characteristics of the diagnostic test used. The legitimacy of Add
Health depends on the representativeness of the original school-based sample, nonresponse to
the Wave III follow-up survey, truthful reporting on sexual experience, and refusal or other
problems that led to a missing diagnostic outcome. The original sample included only
students on school registers, but an evaluation of school dropouts suggests any resultant bias
in Add Health is small (153). Post stratification sample weight adjustment accounted for the
24 percent of Wave I participants who could not be located for Wave III, a bias that was also
small (154). Both the frequency and validity of responses to sensitive questions about sexual
experiences were likely improved through the use of CASI (127-131). Additionally,
participants who did and did not provide urine specimens for STI testing were similar (164).
Earlier analyses show prevalence estimates were robust to differences in characteristics of
non-respondents and diagnostic test performance (3).
This dissertation, complete with multiple limitations, was a worthy public health
endeavor. The research addressed salient gaps in the epidemiology of chlamydial infection
among US young adults, an understudied population. At the very least, the findings can
initiate and inform new dialogue about how best to address racial and ethnic disparities in
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sexual health. Furthermore, this work underscores that more remains to be uncovered about
chlamydial infection and how it moves so effectively across populations.
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APPENDIX ONE
PREVALENCE OF CHLAMYDIA TRACHOMATIS
Table A1.1 Prevalence of Chlamydia trachomatis
First Author
(Reference)
Publication
Year
Study Location Source
Population
Gender Age Range
(Mean)
Test Type Sample
Size
Infection
Prevalence
Millstein SG (167) 1995 San Francisco, CA FP clinics female 13 – 19 (17) culture 571 9.3
Gershman (168) 1996 Statewide, CO FP clinics female NS DNA
probe
12,926 4.5
Stary A (72) 1996 National military recruits male (27) urine LCR
and PCR
705 4.1
Marrazzo JM (44) 1997 Seattle, WA non-traditional
sites
male and
female
(median=16) urine LCR 10,118 6.9
Rietmeijer CA (50) 1997 Denver, CO non-clinic sites male and
female
(17) urine PCR 486 6.6
Schwebke JR (45) 1997 Birmingham, AL STD clinic male and
female
NS swab
culture
14,162 10.9
Beck-Sague CM (169) 1998 Atlanta, GA adolescent
clinics
female 13 – 20 (17) cervical
PCR
451 20.7
Brodine SK (65) 1998 National and
Okinawa, Japan
military
personnel
male and
female
NS urine LCR 1,338 4.2
Burstein GR (42) 1998 Baltimore, MD STD, FP,
school-based
clinics
female 12 – 19 (17) cervical or
urine PCR
3,202 24.1
Burstein GR (135) 1998 Baltimore, MD school-based
clinics
female 12 – 17 (14) urine LCR 170 15.3
Cohen DA (156) 1998 Urban, LA school-based
screening
male and
female
NS urine PCR
and LCR
1,933 6.5
Gaydos CA (43) 1998 Baltimore, MD school-based
clinics
female 13 – 21 (17) urine PCR
and LCR
408 15.7
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First Author
(Reference)
Publication
Year
Study Location Source
Population
Gender Age Range
(Mean)
Test Type Sample
Size
Infection
Prevalence
Gaydos CA (46) 1998 National military recruits female 17 – 39
(median=21)
urine LCR 13,204 9.2
Gunn RA (79) 1998 San Diego, CA non-clinic sites male 15 – 19 urine PCR 261 6.1
Mertz KJ (40) 1998 National NHANES III
sample
male and
female
12 – 39 urine LCR 1,144 3.9
Oh MK (48) 1998 Birmingham, AL juvenile jail male and
female
12 – 18 urine LCR 263 12.2
Bunnell RE (39) 1999 Atlanta, GA teen health
clinics
female 14 – 19
(median=16)
cervical
PCR
635 27.2
Cohen DA (60) 1999 Urban, LA school-based
health centers
males NS urine LCR 2,308 6.2
Cohen DA (60) 1999 Urban, LA school-based
health centers
females NS urine LCR 2,497 11.5
Rosenberg MD (118) 1999 San Francisco, CA STD clinic male and
female
14 – 19 (18) urine LCR 283 17.0
Bachmann LH (170) 2000 Birmingham, AL residential drug
treatment
male and
female
16 – 65
(median=36)
urine LCR 311 2.3
Joyner JL (171) 2000 Denver, CO STD clinic male (32) urine PCR 454 7.5
Pack RP (15) 2000 Birmingham, AL juvenile jail male 14 – 18 (16) urine LCR 284 14.4
Best D (38) 2001 Suburban, NC private pediatric
practice
male and
female
15 – 24
(17.1)
urine LCR 331 2.1
Harrington KF (172) 2001 Birmingham, AL low income
health clinics
female 14 – 18 (16) vaginal
LCR
522 17.1
Klausner JD (173) 2001 San Francisco, CA population-
based household
survey
female 18 – 29 (24) urine LCR 1,314 3.2
Mehta SD (112) 2001 Baltimore, MD emergency
department
male and
female
18 – 44 (28) urine LCR 655 6.7
Mertz KJ (49) 2001 National job training
program
female 16 – 24 cervical
ELISA
141,336 12.5
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First Author
(Reference)
Publication
Year
Study Location Source
Population
Gender Age Range
(Mean)
Test Type Sample
Size
Infection
Prevalence
Bloomfield FP (174) 2002 San Francisco, CA home-based
mail-in testing
male and
female
16 – 67 (41) urine PCR 76 1.3
Ku L (16) 2002 National NSAM male 18 – 19 urine PCR 470 3.1
Ku L (16) 2002 National NSAM male 22 – 26 urine PCR 995 4.5
Turner CF (175) 2002 Baltimore, MD household
probability
sample
male and
female
18 – 35 urine LCR 579 3.0
Wingood GM (176) 2002 South, US schools, health
clinics
female 14 – 18 (16) vaginal
LCR
522 17.5
Farley TA (177) 2003 New Orleans, LA non-traditional
sites
male and
female
18 – 29 (23) urine LCR 1,610 10.2
Monroe KM (80) 2003 Birmingham, AL emergency
department
male and
female
14 – 20 (16) urine LCR 879 6.9
Schwebke JR (178) 2003 Birmingham, AL STD clinic male NS urine LCR 300 19.6
Sutton TL (17) 2003 Fort Lewis, WA ROTC cadets male 18 – 32 (23) urine LCR 1,443 2.5
Bauer HM (179) 2004 24 CA health
jurisdictions
non-clinic sites male and
female
NS urine
NAAT
16,279 6.6
Crosby RA (180) 2004 Atlanta, GA
Providence, RI
Miami, FL
primary care
clinics and
outreach
male and
female
15 – 21 (18) urine LCR 455 7.5
DiClemente RJ (181) 2004 Atlanta, GA hospital prenatal
clinic
female 14 – 20 (17) urine LCR 170 13.0
Miller WC (3) 2004 National Add Health male and
female
18 – 26 (22) urine LCR 12,548 4.2
Nsuami M (182) 2004 Urban, LA school-based
screening
male and
female
12 – 22 (16) urine LCR 5,877 7.7
LCR = ligase chain reaction; PCR = polymerase chain reaction; NAAT = nucleic acid amplification test; NS = not stated; STD =
sexually transmitted disease; FP = family planning; ROTC = reserve officer training corps; NHANES = National Health and Nutrition
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Examination Survey; NSAM = National Survey of Adolescent Males; Add Health = National Longitudinal Study of Adolescent
Health
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APPENDIX TWO
NUCLEIC ACID AMPLIFICATION DIAGNOSTIC TEST CHARACTERISTICS
Table A2.1 Sensitivity and Specificity of Nucleic Acid Amplification Tests for Chlamydia trachomatis
First Author
(Reference)
Publication
Year
Source Population Gender Sample
Size
Infection
Prevalence
Sensitivity Specificity Sensitivity
after DA
Specificity
after DA
Chernesky MA (67) 1994 STD clinic
Hamilton, ON
male 305 17.7 NC NC 96.4 100
Chernesky MA (67) 1994 student health,
abortion clinics
Hamilton, ON
female 447 6.0 93.3 97.0 96.3 100
Bassiri M (68) 1995 FP clinic
Västerås, Sweden
female 447 3.1 87.5
(by EIA)
100
(by EIA)
NS NS
Lee HH (69) 1995 OB, STD, student
health clinics
Birmingham, AL
Seattle, WA
San Francisco, CA
Hamilton, ON
female 1,937 7.7 93.8 99.9 NS NS
van Doornum GJJ
(70)
1995 STD clinic
Amsterdam,
The Netherlands
male 258 9.7 83.3 97.9 86.2 100
van Doornum GJJ
(70)
1995 STD clinic
Amsterdam,
The Netherlands
female 237 10.5 86.7 94.6 78.1 100
Buimer M (71) 1996 STD clinic
Amsterdam,
The Netherlands
male 614 9.9 86.0 95.8 77.3 99.4
Buimer M (71) 1996 STD clinic
Amsterdam,
The Netherlands
female 602 9.1 83.3 94.8 78.8 99.4
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First Author
(Reference)
Publication
Year
Source Population Gender Sample
Size
Infection
Prevalence
Sensitivity Specificity Sensitivity
after DA
Specificity
after DA
Stary A (72) 1996 military recruits,
United Nations
male 705 3.8 45.8
(by EIA)
97.7
(by EIA)
93.1 100
Chernesky MA (73) 1997 STD clinic male 287 11.5 NC NC 94.3 99.6
Goessens WHF (74) 1997 STD clinic
Rotterdam,
The Netherlands
male,
female
1,000 9.7 79.2 95.3 83.7 99.9
Pasternack R (75) 1997 STD, student
health clinics
Tampere, Finland
female 442 10.6 93.2 82.7 94.0 100
Schepetiuk S (76) 1997 STD clinic
Adelaide,
Australia
male,
female
1,005 3.0 91.3 99.1 75.0 100
Morré, SA (77) 1999 general practice
Amsterdam,
The Netherlands
male,
female
2,855 2.6 74.7
(by PCR)
99.6
(by PCR)
78.6 99.7
Black CM (78) 2002 STD clinics
Birmingham, AL
Indianapolis, IN
New Orleans, LA
San Francisco, CA
Seattle, WA
female 3,551 11.4 82.6 96.6 NS NS
Unless stated otherwise, infection prevalence is determined by LCR and sensitivity and specificity using culture as reference standard.
DA = discrepant analysis; NC = not calculable; NS = not stated; EIA = enzyme immunofluorescent assay; PCR = polymerase chain
reaction; LCR = ligase chain reaction; STD = sexually transmitted disease; OB = obstetric.
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APPENDIX THREE
SELECTIVE SCREENING CRITERIA FOR CHLAMYDIAL INFECTION
Table A3.1 Selective Screening Criteria for Chlamydia trachomatis in Women
Reference (81) (82) (83) (84)
Risk Assessment Criteria any 1 # or
age specific
any 1 # any 1 # any 1 #
Demographic Markers
age < 20 years #
age < 20 years
age < 21 years # #
age < 24 years (with 1 º) #
age > 24 years (with 2 º)
age < 25 years
age < 30 years
unmarried
African American
nulliparous
Behavioral Markers
barrier contraception use
(none)
º
barrier contraception use
(inconsistent: < 100%)
º
new sex partner (1 month)
new sex partner (2-3 months) º
> 2 sex partners (2-3 months) º
new sex partner (1 year)
> 2 sex partners (1 year)
partner with STI
partner with multiple partners
douching (1 year)
Symptoms
frequent urination
intermenstrual bleeding
Physical Findings
cervical friability
cervical ecotopy
mucropurulent discharge #
Additional Diagnoses
PID
prior STI
gonorrheal infection
genital warts
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Reference (88) (89) (87) (14)
Risk Assessment Criteria any 1 # or
age specific
any 1 # or
age specific
any 1 # any 1 #
Demographic Markers
age < 20 years
age < 20 years
age < 21 years
age < 24 years # #
age > 24 years (with 1 º) (with 1 º)
age < 25 years #
age < 30 years #
unmarried
African American
nulliparous
Behavioral Markers
barrier contraception use
(none)
barrier contraception use
(inconsistent: < 100%)
new sex partner (1 month)
new sex partner (2-3 months)
> 2 sex partners (2-3 months)
new sex partner (1 year) º
> 2 sex partners (1 year) º
partner with STI º
partner with multiple partners
douching (1 year)
Symptoms
frequent urination
intermenstrual bleeding
Physical Findings
cervical friability º
cervical ecotopy º
mucropurulent discharge º
Additional Diagnoses
PID
prior STI
gonorrheal infection
genital warts
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Reference (90) (91) (92) (85)
Risk Assessment Criteria any 1 # any 1 # any 1 # any 1 #
Demographic Markers
age < 20 years
age < 20 years # #
age < 21 years
age < 24 years #
age > 24 years
age < 25 years #
age < 30 years
unmarried #
African American #
nulliparous
Behavioral Markers
barrier contraception use
(none)
barrier contraception use
(inconsistent: < 100%)
#
new sex partner (1 month) #
new sex partner (2-3 months)
> 2 sex partners (2-3 months)
new sex partner (1 year) # #
> 2 sex partners (1 year) #
partner with STI # #
partner with multiple partners
douching (1 year)
Symptoms
frequent urination #
intermenstrual bleeding #
Physical Findings
cervical friability #
cervical ecotopy #
mucropurulent discharge # #
Additional Diagnoses
PID #
prior STI #
gonorrheal infection
genital warts
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Reference (93) (94) (95) – I (95) – II
Risk Assessment Criteria any 2 # >2 # or >3 # >3 # or >4 # sum > 4 or
>5
Demographic Markers
age < 20 years
age < 20 years
age < 21 years
age < 24 years # # # 1
age > 24 years
age < 25 years
age < 30 years
unmarried # # 2
African American # 1
nulliparous # 1
Behavioral Markers
barrier contraception use
(none)
# #
barrier contraception use
(inconsistent: < 100%)
new sex partner (1 month)
new sex partner (2-3 months) # #
> 2 sex partners (2-3 months)
new sex partner (1 year)
> 2 sex partners (1 year) # 1
partner with STI
partner with multiple partners
douching (1 year) # 1
Symptoms
frequent urination
intermenstrual bleeding
Physical Findings
cervical friability # #
cervical ecotopy # 2
mucropurulent discharge #
Additional Diagnoses
PID
prior STI
gonorrheal infection
genital warts
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Reference (58) (96) (97) – I (97) – II
Risk Assessment Criteria sum
> 3
any 1 # any 1 # any 1 #
Demographic Markers
age < 20 years
age < 20 years
age < 21 years
age < 24 years 1
age > 24 years
age < 25 years
age < 30 years
unmarried
African American 2
nulliparous 1
Behavioral Markers
barrier contraception use
(none)
barrier contraception use
(inconsistent: < 100%)
new sex partner (1 month)
new sex partner (2-3 months) #
> 2 sex partners (2-3 months) #
new sex partner (1 year) #
> 2 sex partners (1 year) 1
partner with STI #
partner with multiple partners
douching (1 year) 1
Symptoms
frequent urination # #
intermenstrual bleeding # #
Physical Findings
cervical friability # # #
cervical ecotopy
mucropurulent discharge # # #
Additional Diagnoses
PID # # #
prior STI
gonorrheal infection #
genital warts # #
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APPENDIX FOUR
VARIABLE DERIVATION AND CODING SCHEMES
Individual Characteristics, Sociodemographic
Gender: Respondent’s gender was confirmed by the interviewer [BIO_SEX3] and coded as
1 = male, 2 = female. This will be recoded as 0 = male, 1 = female.
Age: The respondent’s age during the interview month will be calculated by subtracting the
birth month and year from the interview month and year.
• Confirm birth date [H3OD1M, H3OD1Y].
Age will be examined as a continuous measure and categorized according to risk level
observed in the data.
Race/Ethnicity: A five-level variable for participant’s race/ethnicity will be coded through a
multi-step process. A single race will first be identified for each participant. For participants
reporting just one race, this is their race designation. The race designation for participants
reporting multiple races will be their response to the one “best” racial background question.
After identifying a single race for each subject, race and ethnicity will be examined in
tandem. All participants responding affirmatively to the question of Hispanic or Latino
origin will be coded as Latino. Participants not identifying as Hispanic or Latino will be
coded according to their single best race designation: white, black, Asian American or
Native American.
• Are you of Hispanic or Latino origin [H3OD2]?
• What is your race? You may give more than one answer [H3OD4A – D].
• Which one category best describes your racial background [H3OD6]?
Analyses will also be conducted on a subset of the population restricted to white, black, and
Latino. All race/ethnicity variables will be coded with indicator coding.
Region: Participants were assigned one of the US census regions (northeast, Midwest, south,
west) based on Wave III residence. This variable will be kept categorical and dichotomized
to reflect disparate prevalence measures with 0 = outside southern US and 1 = southern US.
Marital status: Participants were asked
• How many times have you been married [H3MR1]?
• Are you still married [H3MR3_A-C]?
These two questions will be combined to create a dichotomous variable with 0 = not married
and 1 = married.
Housing: Participants were asked
• Where do you live now? That is, where do you stay most often [H3HR2]?
Housing was dichotomized with 0 = no shared housing and 1 = shared housing.
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Student status: Participants were asked
• Are you currently attending regular school? If you are enrolled but on a school break
or vacation, count this as attending [H3ED23].
The coded response of 0 = no and 1 = yes will be retained.
Highest attained education: Participants were asked a series of questions about their
education.
• What is the highest grade or year of regular school you have completed [H3ED1]?
• What degrees or diplomas have your received? Indicate all that apply.
° GED or high school equivalency [H3ED2]
° high school diploma [H3ED3]
° associate or junior college degree – an AA [H3ED4]
° bachelor’s degree – a BA, AB, or BS [H3ED5]
° master’s degree – an MA or MS [H3ED6]
° doctoral degree – a PhD, DrPH, and so on [H3ED7]
° professional degree – a DDS, JD, MD, DVM, and so on [H3ED8]
• Is it correct that you have received no academic degree or diploma [H3ED9]?
The responses to these questions will be used to develop highest attained education as a
categorical variable. The possibility of a linear relationship between education and STI will
be examined to judge the validity of education as an ordered categorical variable using
tertiles, quartiles or quintiles of highest education completed. More likely, education will be
used a nominal categorical variable with indicator coding.
Employment status: Participants were asked
• Are you currently working for pay for at least 10 hours a week [H3LM7]?
The coded response of 0 = no and 1 = yes will be retained.
Military status: Participants were asked
• Are you currently serving in the full-time active-duty military [H3LM39]?
• Have you ever served in the active-duty military [H3LM43]?
Indicator variables will be used to account for a three-level categorization: never military,
former military, and current military. This variable will also be dichotomized at 0 = never
military and 1 = ever military.
Functional income: Participants were asked
• In the past 12 months, was there a time when you didn’t pay the full amount of the
rent or mortgage because you didn’t have enough money [H3EC19]?
• In the past 12 months, was there a time when you didn’t pay the full amount of a gas,
electricity, or oil bill because you didn’t have enough money [H3EC21]?
Functional income combined these two questions into 0 = no problem paying either and 1 =
problem paying at least one.
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Individual characteristics, Behavioral
Age at sexual debut: Participants were asked
• Have you ever had vaginal intercourse? (Vaginal intercourse is when a man inserts
his penis into a woman’s vagina) [H3SE1].
• How old were you the first time you had vaginal intercourse [H3SE2]?
Sexual debut will be used as a continuous variable and categorized to reflect patterns in the
data.
Number of sex partners, lifetime: Participants were asked
• With how many partners have you ever had vaginal intercourse [H3SE3]?
This variable will be examined continuously and categorized to reflect the data distribution.
Number of sex partners, past 12 months: Participants were asked
• With how many different partners have you had vaginal intercourse in the past 12
months [H3SE4]?
This variable will be examined continuously and categorized to reflect the data distribution.
Current stable partnership: Participants were asked
• Are you currently involved in a sexual or romantic relationship with
{initials}[H3TR1]?
• Has your relationship with {initials} lasted for at least three months in total [H3TR2]?
These dichotomous variables will be combined to create a new dichotomous variable with 0
= current partnership > 3months duration, 1 = no current partnership > 3 months duration.
Concurrent sex partners, past 12 months: Participants were asked to list all relationships
since summer 1995 and asked
• Have you had sexual relations with {initials}? By “sexual relations” we mean
vaginal intercourse, oral sex, or anal sex [H3TR8].
Participants answered detailed questions for each relationship identified as sexual, including
the beginning and ending dates of the sexual relationship.
• In what month and year did your sexual relationship with <partner> begin
[H3RD10M/Y]?
• In what month and year did your sexual relationship with <partner> end
[H3RD20M/Y]?
Overlaps in sexual relationships can be identified through these responses. This variable will
be dichotomized at 0 = no concurrent relationship and 1 = concurrent relationship.
Condom frequency, past 12 months: Participants were asked
• On how many of [the times you had vaginal intercourse] did you/your partner use a
condom [H3SE8]?
Possible responses were 0 = none, 1 = some, 2 = half, 3 = most, or 4 = all. This variable will
be examined as ordered categorical, as nominal categorical using four indicator variables,
and dichotomized at 0 = 100% condom use and 1 = less than 100% condom use.
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Paid or been paid for sex, past 12 months: This variable will be developed from responses to
four questions.
• Have you ever paid someone to have sex with you [H3SE15]?
• In the past 12 months, how many times have you paid someone to have sex with you
[H3SE16]?
• Have you ever had sex with someone who paid you to do so [H3SE17]?
• In the past 12 months, how many times have you had sex with someone who paid you
to do so [H3SE18]?
A dichotomous variable with 0 = no payment for sex in past 12 months and 1 = payment for
sex in past 12 months will be created.
Regrettable sex after drinking or drugs, past 12 months: Participants were asked
• Over the past 12 months, how many times did you get into a sexual situation that you
later regretted because you had been drinking [H3TO48C]?
• During the past 12 months, how often did you get into a sexual situation that you later
regretted because you had been using drugs [H3TO126]?
These questions will be combined to create a single dichotomous variable with 0 = no
regrettable sexual situations after drinking or drugs in past 12 months and 1 = regrettable
sexual situations after drinking or drugs in the past 12 months.
Sexuality: Participants were asked
• Please choose the description that best fits how you think about yourself [HSSE13].
Sexuality was dichotomized at 0 = 100% heterosexual and 1 = not 100% heterosexual.
Individual Characteristics, Risk Perception
Perceived risk of STD: Participants were asked on a five-point likert scale ranging from very
high chance to very low chance
• What is the chance that right now you have either gonorrhea or chlamydia [H3SE32]?
The likert scale will be retained.
Perceived risk of HIV: Participants were asked on a five-point likert scale ranging from
almost certain to almost no chance
• What do you think are the chances that you will get HIV or AIDS [H3EC61]?
The likert scale will be retained.
Individual Characteristics, Medical/Health Care
Recent health care utilization: Participants were asked about three separate events of health
care utilization.
• How long ago did you last consult a doctor or nurse [H3HS11]?
• How long ago did you last have a routine check-up [H3HS14]?
• When was the last time you had a gynecological or pelvic exam [H3HS16]?
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These are ordered categorical variables that range from within the past three months to two
years ago or longer. The most recent of the three responses will be kept as an ordered
variable if it is linear in the logit and more coarsely categorized based on the variable
distribution.
Current insurance status: Participants were asked about if they have health insurance and
through whom they have it.
• Which of the following best describes your current health insurance situation
[H3HS5]?
This variable will be dichotomized to 0 = insurance and 1 = no insurance.
Forgone care, past 12 months: Participants were asked
• Has there been any time in the past 12 months when you thought you should get
medical care, but you did not [H3HS6]?
The coded response of 0 = no and 1 = yes will be retained.
Antibiotic use, past 30 days: Participants were asked
• In the past 30 days, have you taken antibiotics, such as tetracycline, doxycycline,
amoxicillin, or erythromycin [H3ID12]?
The coded response of 0 = no and 1 = yes will be retained.
Tested for STD, past 12 months: Participants were asked about testing for numerous STDs.
• Which, if any, of the following sexually transmitted diseases have you been tested for
in the past 12 months?
° chlamydia [H3SE22A]
° gonorrhea [H3SE22B]
° trichomoniasis [H3SE22C]
° syphilis [H3SE22AD]
° genital herpes [H3SE22E]
° genital warts [H3SE22F]
° human papilloma virus (HPV) [H3SE22G]
° bacterial vaginosis [H3SE22H]
° pelvic inflammatory disease (PID) [H3SE22I]
° cervicitis or mucopurulent cervicitis (MPC) [H3SE22J]
° urethritis (NGC) [H3SE22K]
° vaginitis [H3SE22L]
° HIV infection or AIDS [H3SE22M]
° other [H3SE22N]
These variables will be grouped together to identify participants who had been tested for any
STD in the past 12 months. The variable will be dichotomized at 0 = no STD testing and 1 =
STD testing.
Prior STD: Participants were asked about diagnosis of numerous STDs.
• In the past 12 months, have you been told by a doctor or nurse that you had the
following sexually transmitted disease?
° chlamydia [H3SE21A]
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° gonorrhea [H3SE21B]
° trichomoniasis [H3SE21C]
° syphilis [H3SE21AD]
° genital herpes [H3SE21E]
° genital warts [H3SE21F]
° human papilloma virus (HPV) [H3SE21G]
° bacterial vaginosis [H3SE21H]
° pelvic inflammatory disease (PID) [H3SE21I]
° cervicitis or mucopurulent cervicitis (MPC) [H3SE21J]
° urethritis (NGC) [H3SE21K]
° vaginitis [H3SE21L]
° HIV infection or AIDS [H3SE21M]
° other [H3SE21N]
These variables will be grouped together to identify participants who have been diagnosed
with any STD in the past 12 months. The variable will be dichotomized at 0 = no prior STD
and 1 = prior STD.
STD-like genitourinary symptoms: Participants were asked about STD-like symptoms in the
past 12 months and in the past 24 hours.
• In the past 12 months/24 hours, have you had any of the following symptoms?
° painful or very frequent urination (peeing) [H3SE23A, 24A]
° painful sores or blisters on your genitals [H3SE23B, 24B]
° warts on your genitals [H3SE23C, 24C]
° dripping or oozing from your penis/vagina [H3SE23D, 24D]
° bleeding after intercourse or between your periods [H3SE23E, 24E]
° itching in the vagina or in the genital area [H3SE23F, 24F]
These variables will be examined for both past 12 months and past 24 hours. The variables
will be dichotomized at 0 = no symptoms and 1 = symptoms.
Parity: Participants were asked about the number completed pregnancies with a separate
response to indicate women who are currently pregnant.
• Please indicate how many babies were born alive [H3TP3].
This variable will be categorized several ways. It will be dichotomized at 0 = no current
pregnancy and 1 = current pregnancy and at 0 = never pregnant and 1 = pregnant.
Hormonal contraception use: Participants were asked
• In the past 12 months, which of the following methods of birth control have you/has a
female partner of yours used [H3SE29A – H3SE29C]?
Contraception was dichotomized with 0 = contraception and 1 = no contraception.
Partner Characteristics
Gender: All analyses will be restricted to heterosexual relationships. Participants were asked
• Please indicate whether your partner is male or female [H3TR3].
Responses were coded as 1 = male, 2 = female. This will be recoded as 0 = male, 1 = female.
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Age: Partner’s age is available as a constructed Add Health variable based on responses to
questions the partner age difference [PAGE].
• Please indicate whether your partner is older or younger than you [H3TR4].
• How may years older/younger than you is your partner [H3TR5]?
Partner age will be examined continuously and categorized to best reflect data patterns and
distributions.
Age difference: Age difference is available for all relationships since summer 1995
[H3TR5]. The age difference will be identified for the most recent partner and for the
partner in the past year with the greatest age difference. Age difference will be assessed
continuously and categorized based on the distribution of the variable in the data.
Race/ethnicity: Participants were asked
• Please indicate the race of your partner [H3TR6].
• Is your partner of Hispanic or Latino origin [H3TR7]?
Participants could place their partner in one of four categories: white, black, Asian American
or Native American. A five-level variable for partner’s race/ethnicity will be coded by
examining race and ethnicity in tandem. All partners identified as Hispanic or Latino will be
coded as Latino. Partners not identified as Hispanic or Latino will be coded according to
their race designation: white, black, Asian American or Native American. Analyses will
also be conducted on a subset of the population restricted to white, black, and Latino. All
race/ethnicity variables will be coded with indicator coding.
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